{"Title": ["First Week of CORT February 2021 Options Trading", "7 Great Biotech Stocks to Buy and Hold Now", "Validea Joel Greenblatt Strategy Daily Upgrade Report - 6/5/2020", "Noteworthy Tuesday Option Activity: WING, CORT, DIS", "Should You Climb on Board the Corcept Therapeutics Train?", "Validea Joel Greenblatt Strategy Daily Upgrade Report - 5/8/2020", "Health Care Sector Update for 05/05/2020: CEMI, GNMK, CORT, XLV, VHT, IYH", "Corcept Therapeutics Incorporated (CORT) Q1 2020 Earnings Call Transcript", "First Week of CORT February 2021 Options Trading", "Corcept Therapeutics Incorporated (CORT) Q4 2019 Earnings Call Transcript", "Validea's Top Five Healthcare Stocks Based On Motley Fool - 2/16/2020", "Validea Motley Fool Strategy Daily Upgrade Report - 2/4/2020", "Analysts Anticipate PJP Will Reach $73", "Corcept Therapeutics Enters Oversold Territory (CORT)", "How The Pieces Add Up: PBE Targets $62", "FTXH's Holdings Could Mean 15% Gain Potential", "Validea Joel Greenblatt Strategy Daily Upgrade Report - 2/26/2020", "CORT Crosses Above Average Analyst Target", "Corcept Therapeutics Incorporated (CORT) Q3 2019 Earnings Call Transcript", "Notable Friday Option Activity: JPM, MU, CORT", "Interesting CORT Put And Call Options For December 20th", "Sum Up The Pieces: FAD Could Be Worth $82", "Corcept Therapeutics Incorporated (CORT) Q2 Earnings Call Transcript", "First Week of February 2020 Options Trading For Corcept Therapeutics (CORT)", "Here's Why Corcept Therapeutics Stock Hit the Bricks Today", "Corcept (CORT) Down 6.1% Since Last Earnings Report: Can It Rebound?", "Here's Why Corcept Therapeutics Shares Rose 11.5% in February", "Corcept (CORT) Q4 Earnings Beat Estimates, Revenues In Line", "Corcept Therapeutics Incorporated (CORT) Q4 2018 Earnings Conference Call Transcript", "Earnings Reaction History: CORCEPT THERAPT, 33.3% Follow-Through Indicator, 5.4% Sensitive", "Options Traders Expect Huge Moves in Corcept (CORT) Stock", "Here's Why Corcept Therapeutics Fell as Much as 13.7% Today", "Corcept Therapeutics Incorporated (CORT) Q1 2019 Earnings Call Transcript", "Here's Why Corcept Therapeutics Stock Fell as Much as 18.5% Today", "First Week of CORT March 15th Options Trading", "Notable Wednesday Option Activity: BLK, ALGN, CORT", "CORT Crosses Above Key Moving Average Level", "CORT Crosses Above Average Analyst Target", "Notable Wednesday Option Activity: CORT, XPO, COST", "2 Marijuana Stocks Among 4 Charts Looking Higher", "Noteworthy Monday Option Activity: DHT, CORT, EXPE", "Here's Why Corcept Therapeutics Surged Today", "Here's Why Corcept Therapeutics Rose 18.6% in November", "Corcept Initiates Phase III Study for Cushing's Syndrome", "Corcept (CORT) Q3 Earnings In Line, Revenues Miss Estimates", "Corcept Therapeutics (CORT) Meets Q3 Earnings Estimates", "How The Pieces Add Up: IJT Targets $215", "Do Options Traders Know Something About Corcept (CORT) Stock We Don't?", "Wednesday's ETF with Unusual Volume: SMLF", "Friday 8/17 Insider Buying Report: CORT, CNNE", "Here's Why Corcept Therapeutics Inc. Fell as Much as 17.4% Today", "Corcept (CORT) Earnings and Revenues Miss Estimates in Q2", "Corcept Therapeutics (CORT) Misses Q2 Earnings and Revenue Estimates", "Earnings Reaction History: Corcept Therapeutics Incorporated, 40.0% Follow-Through Indicator, 6.5% Sensitive", "Notable Wednesday Option Activity: CORT, ADBE, ZN", "Validea Motley Fool Strategy Daily Upgrade Report - 7/7/2018", "3 High-Growth Stocks That Could Soar", "Friday 8/17 Insider Buying Report: CORT, CNNE", "Here's Why Corcept Therapeutics Inc. Fell as Much as 17.4% Today", "Corcept (CORT) Earnings and Revenues Miss Estimates in Q2", "Corcept Therapeutics (CORT) Misses Q2 Earnings and Revenue Estimates", "Tuesday's ETF Movers: IHE, GDXJ", "Why Is Corcept Therapeutics (CORT) Up 5.3% Since Its Last Earnings Report?", "Validea's Top Five Healthcare Stocks Based On Motley Fool - 3/18/2018", "Options Traders Expect Huge Moves in Corcept Therapeutics (CORT) Stock", "Corcept Plans Korlym Label Expansion, Pipeline in Progress", "Corcept Therapeutics (CORT) Shares Cross Above 200 DMA", "Corcept's (CORT) Earnings and Sales Meet Estimates in Q4", "Validea's Top Five Healthcare Stocks Based On Motley Fool - 2/18/2018", "Why Corcept Therapeutics Stock Gained 27.4% in January", "CORT Crosses Below Key Moving Average Level", "Mid-Day Market Update: Dow Falls Over 250 Points; Enphase Energy Shares Spike Higher", "Why Corcept Therapeutics Incorporated Lost 34% in February", "Corcept Plans Korlym Label Expansion, Pipeline in Progress", "Corcept Therapeutics (CORT) Shares Cross Above 200 DMA", "Corcept's (CORT) Earnings and Sales Meet Estimates in Q4", "La Jolla Pharmaceutical Meets 80-Plus Relative Strength Rating Benchmark", "Thursday's ETF Movers: PJP, RWR", "Biotech Roundup: Who's Popping On Drug, Merger, Earnings News?", "Omeros Shows Rising Price Performance With Jump To 81 RS Rating", "Mid-Morning Market Update: Markets Open Lower; Bristol-Myers Profit Tops Expectations", "Why Corcept Therapeutics Incorporated Stock Is Getting Clobbered Today", "Omeros Trying To Close In On Key Technical Measure", "20 of the Best Stocks You Probably Haven't Heard Of", "Innoviva Clears Technical Benchmark, Hitting 80-Plus RS Rating", "Stocks Showing Market Leadership: Concert Pharmaceuticals Earns 93 RS Rating", "Regenxbio Earns Relative Strength Rating Upgrade; Hits Key Benchmark", "GW Pharmaceuticals Meets 80-Plus Relative Strength Rating Benchmark", "Regenxbio Clears Technical Benchmark, Hitting 80-Plus RS Rating", "Aerie Pharmaceuticals Sees IBD RS Rating Improve To 74", "Stocks With Rising Relative Strength: La Jolla Pharmaceutical", "Stocks Showing Improved Relative Strength: Omeros", "Stocks Showing Improved Relative Strength: Regenxbio", "Stocks Showing Market Leadership: Array Biopharma Earns 96 RS Rating", "Bioverativ Earns Relative Strength Rating Upgrade", "Stocks Flashing Renewed Technical Strength: Exelixis", "Alder Biopharmaceuticals Shows Rising Price Performance With Jump To 85 RS Rating", "Agios Pharmaceuticals Joins Rank Of Stocks With RS Ratings Over 90", "Stocks To Watch: Acorda Therapeutics Sees RS Rating Jump To 84", "IBD Rating Upgrades: Innoviva Shows Improved Technical Strength", "The 10 Best Stocks of President Trump's First Year", "Stocks With Rising Relative Strength: Biogen", "New Highs By Biotech, Solar Stocks Test Investor Conviction", "Stocks Showing Market Leadership: Voyager Therapeutics Earns 91 RS Rating", "TG Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating", "Agios Pharmaceuticals Joins Rank Of Stocks With RS Ratings Over 90", "Stocks To Watch: Acorda Therapeutics Sees RS Rating Jump To 84", "IBD Rating Upgrades: Innoviva Shows Improved Technical Strength", "Stocks To Watch: Halozyme Therapeutics Sees RS Rating Rise To 92", "Alder Biopharmaceuticals Meets 80-Plus Relative Strength Rating Benchmark", "Heron Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90", "Stocks With Rising Relative Price Strength: Regenxbio", "Atara Biotherapeutics Joins Elite Club Of Stocks With RS Ratings Over 90", "Stocks Showing Market Leadership: Array Biopharma Earns 91 RS Rating", "Portola Pharmaceuticals Reaches 80-Plus Relative Strength Rating Benchmark", "Avexis Joins Rank Of Stocks With RS Ratings Over 90", "PTC Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating", "Stocks Showing Market Leadership: CRISPR Therapeutics Earns 92 RS Rating", "Stocks Generating Improved Relative Strength: Supernus Pharmaceuticals", "Trevena Announces FDA Acceptance of Olinvo NDA, Shares Up", "Supernus Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Threshold", "Stocks Showing Market Leadership: Array Biopharma Earns 91 RS Rating", "PTC Therapeutics Shows Market Leadership With Jump To 84 RS Rating", "La Jolla Pharmaceutical Hits 80-Plus Relative Strength Rating Benchmark", "TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise", "Flexion Therapeutics Getting Closer To Key Technical Measure", "Supernus Pharmaceuticals Shows Rising Price Performance With Jump To 81 RS Rating", "Achaogen's NDA for Plazomicin Gets Priority Review From FDA", "5 Reasons to Invest in Novo Nordisk (NVO) Stock Right Now", "Stocks Generating Improved Relative Strength: Biogen", "PTC Therapeutics Shows Market Leadership With Jump To 84 RS Rating", "La Jolla Pharmaceutical Hits 80-Plus Relative Strength Rating Benchmark", "TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise", "Alexion's (ALXN) Soliris Label Expansion Approved in Japan", "Innoviva Sees RS Rating Rise To 74", "What Drives Catalyst Pharmaceuticals Above 250% This Year?", "Merck's Diabetes Drugs Get FDA Nod as Adjunct Therapies", "BioMarin's (BMRN) Pegvaliase Review Period Extended by FDA", "Portola's (PTLA) AndexXa BLA Review Period Extended by FDA", "PTC Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating", "Stocks Showing Improving Market Leadership: Voyager Therapeutics Earns 84 RS Rating", "Array Biopharma Shows Rising Price Performance With Jump To 85 RS Rating", "Stocks Showing Market Leadership: Exelixis Earns 93 RS Rating", "IBD Rating Upgrades: Pacira Pharmaceuticals Shows Improved Relative Price Strength", "Merck's Diabetes Drugs Get FDA Nod as Adjunct Therapies", "BioMarin's (BMRN) Pegvaliase Review Period Extended by FDA", "Portola's (PTLA) AndexXa BLA Review Period Extended by FDA", "PTC Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating", "Stocks Showing Improving Market Leadership: Voyager Therapeutics Earns 84 RS Rating", "Array Biopharma Shows Rising Price Performance With Jump To 85 RS Rating", "Strength Seen in Corcept Therapeutics (CORT): Stock Soars 10.8%", "Jazz Submits NDA to FDA for JZP-110 to Cure Sleep Disorder", "Corcept Therapeutics Shows Rising Price Performance With Jump To 95 RS Rating", "Radius Health to Get Third Day-180 List of Outstanding Issues", "GW Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Benchmark", "Clovis Oncology Shows Rising Relative Strength; Still Shy Of Key Threshold", "Stocks With Rising Relative Strength: PTC Therapeutics", "Alnylam/Sanofi Submit MAA in Europe for RNAi Candidate", "Stocks Showing Improved Relative Strength: Acceleron Pharma", "Avexis Shows Market Leadership With Jump To 93 RS Rating", "Array Biopharma Scores Relative Strength Rating Upgrade; Hits Key Benchmark", "Glaxo's Nucala Label Expansion Application Gets FDA Approval", "Proteostasis Stock Surges on Positive Data From CF Studies", "Regeneron, Sanofi Report Positive Top Line Skin Cancer Data", "Allergan Inks Deal to Buy Texas-Based Repros Therapeutics", "Shire's New Formulation of Oncaspar Gets Approval in Europe", "Stocks Showing Improving Market Leadership: Pacira Pharmaceuticals Earns 81 RS Rating", "Spark Therapeutics Stock Plunges on Hemophilia Therapy Data", "Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma", "Biogen Sees RS Rating Rise To 72", "Acceleron Pharma Sees RS Rating Climb To 74", "Spark Therapeutics Trying To Close In On Key Technical Benchmark", "Stocks Generating Improved Relative Strength: Supernus Pharmaceuticals", "Stocks Showing Improved Relative Strength: Supernus Pharmaceuticals", "Stocks Showing Improving Market Leadership: Pacira Pharmaceuticals Earns 81 RS Rating", "Spark Therapeutics Stock Plunges on Hemophilia Therapy Data", "Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma", "Biogen Sees RS Rating Rise To 72", "Acceleron Pharma Sees RS Rating Climb To 74", "Spark Therapeutics Trying To Close In On Key Technical Benchmark", "Stocks Generating Improved Relative Strength: Supernus Pharmaceuticals", "Stocks Showing Improved Relative Strength: Supernus Pharmaceuticals", "Stocks Showing Improving Market Leadership: Pacira Pharmaceuticals Earns 81 RS Rating", "Spark Therapeutics Stock Plunges on Hemophilia Therapy Data", "Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma", "Biogen Sees RS Rating Rise To 72", "Acceleron Pharma Sees RS Rating Climb To 74", "Sucampo Pharmaceuticals Clears Technical Benchmark, Hitting 80-Plus RS Rating", "Spark Therapeutics Trying To Close In On Key Technical Measure", "Aerie Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating", "Lilly Reports Mixed Results from Late-Stage Cyramza Study", "Pacira Pharmaceuticals Sees RS Rating Climb To 75", "Sucampo Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Threshold", "Regenxbio Joins Rank Of Stocks With RS Ratings Over 90", "Roche Reports Tecentriq/Avastin Lung Cancer Study Data", "Sucampo Pharmaceuticals Clears Technical Benchmark, Hitting 80-Plus RS Rating", "Spark Therapeutics Trying To Close In On Key Technical Measure", "Aerie Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating", "Lilly Reports Mixed Results from Late-Stage Cyramza Study", "Pacira Pharmaceuticals Sees RS Rating Climb To 75", "Sucampo Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Threshold", "Regenxbio Joins Rank Of Stocks With RS Ratings Over 90", "Roche Reports Tecentriq/Avastin Lung Cancer Study Data", "Sucampo Pharmaceuticals Clears Technical Benchmark, Hitting 80-Plus RS Rating", "Spark Therapeutics Trying To Close In On Key Technical Measure", "Aerie Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating", "Revance's Neuromodulator Injection Positive in Phase III", "Here's Why Sarepta Stock is Up More Than 70% in 6 Months", "AstraZeneca's COPD Drug Succeeds in Label Expansion Study", "Ironwood Succeeds in Diabetic Hypertension Phase II Study", "IBD Rating Upgrades: Agios Pharmaceuticals Flashes Improved Relative Price Strength", "Pfizer Wins China & Asia-Pacific Rights to Anti-Fungal Drug", "3 Highest Growth Stocks in the Market Today", "Bristol-Myers' Opdivo's Lung Cancer Study Meets Early Success", "Sage Therapeutics Shows Rising Price Performance With Jump To 91 RS Rating", "Can Valeant (VRX) Turn Around on Rebuilding Initiatives?", "Alnylam Starts Rolling NDA Submission for RNAi Candidate", "Incyte (INCY) Initiates Essential Thrombocythemia Trial", "Stocks Flashing Renewed Technical Strength: Regenxbio", "Ionis Pharmaceuticals Shows Market Leadership With Jump To 81 RS Rating", "Stocks To Watch: Flexion Therapeutics Sees RS Rating Jump To 83", "Exelixis Clears Technical Benchmark, Hitting 80-Plus RS Rating", "Roche (RHHBY) Receives FDA Clearance for Ventana MMR Test", "Pacira's Exparel sNDA to be Reviewed by FDA Advisory Committee", "Cardinal Health (CAH) to Divest Assets to Shanghai Pharma", "Stocks Showing Market Leadership: Zynerba Pharmaceuticals Earns 91 RS Rating", "Shire Gets Positive CHMP Opinion for Hemophilia A Drug", "Alnylam RNAi Drug Gets Accelerated Assessment Grant From EMA", "Glaxo's Subcutaneous Formulation of Benlysta Approved in EU", "Valeant (VRX) Announces Pricing of Senior Secured Notes", "The Zacks Analyst Blog Highlights: Micron Technology, Meritor, RH, Ultra Clean Holdings and Corcept Therapeutics", "Stocks To Watch: Intra-Cellular Therapies Sees RS Rating Rise To 88", "5 Stocks That Doubled in 2017 and Can Keep Soaring Higher", "Stocks With Rising Relative Price Strength: Achaogen", "Top-Rated Stocks: Xoma Sees Composite Rating Climb To 96", "Emergent Biosolutions Shows Market Leadership With Jump To 93 RS Rating", "Biogen Shows Rising Relative Strength; Still Shy Of Key Threshold", "Omeros Scores Relative Strength Rating Upgrade; Hits Key Benchmark", "Why Investors Should Be Excited About Corcept Therapeutics Plunging as Much as 18%", "Acadia Pharmaceuticals Scores Relative Strength Rating Upgrade; Hits Key Threshold", "Stocks Showing Market Leadership: Neurocrine Biosciences Earns 96 RS Rating", "Exelixis Scores Relative Strength Rating Upgrade", "Corcept (CORT) Q3 Earnings Miss Estimates, Guidance Raised", "Small-Cap Biotech Dips As Sales Top, But Earnings Miss By 2 Cents", "Biogen Sees IBD RS Rating Climb To 73", "Flexion Therapeutics Getting Closer To Key Technical Measure", "Sarepta Therapeutics Clears Key Benchmark, Hitting 90-Plus RS Rating", "Stocks Flashing Renewed Technical Strength: Adamas Pharmaceuticals", "Intra-Cellular Therapies Earns Relative Strength Rating Upgrade", "IBD Rating Upgrades: Seattle Genetics Flashes Improved Price Strength", "Stocks To Watch: Adamas Pharmaceuticals Sees Relative Strength Rating Jump To 82", "La Jolla Pharmaceutical Earns Relative Strength Rating Upgrade", "Adamas Pharmaceuticals Clears Technical Benchmark, Hitting 80-Plus RS Rating", "Biogen Sees Relative Strength Rating Climb To 75", "Aimmune Therapeutics Scores Relative Strength Rating Upgrade", "Innoviva Clears Key Benchmark, Hitting 80-Plus RS Rating", "Gilead Sciences Shows Rising Relative Price Performance; Still Shy Of Key Threshold", "Stocks Showing Market Leadership: PTC Therapeutics Earns 92 RS Rating", "Exelixis Earns Relative Strength Rating Upgrade", "Stocks Showing Improving Market Leadership: Five Prime Therapeutics Earns 83 RS Rating", "Intra-Cellular Therapies Shows Rising Price Performance With Jump To 83 RS Rating", "3 Small, Profitable Biotechs With Fantastic Growth", "Aerie Pharmaceuticals Scores Relative Strength Rating Upgrade", "Stocks Showing Rising Market Leadership: Aerie Pharmaceuticals Earns 82 RS Rating", "Dow Returns to All-Time Highs", "Mid-Morning Market Update: Markets Open Higher; Wal-Mart Reports $20B Buyback Plan", "Flexion Therapeutics Clears Technical Benchmark, Hitting 90-Plus RS Rating", "Stocks Showing Improving Market Leadership: Intra-Cellular Therapies Earns 83 RS Rating", "Flexion Therapeutics Hits 80-Plus Relative Strength Rating Benchmark", "Stocks With Rising Relative Price Strength: Ionis Pharmaceuticals", "Stocks To Watch: Adamas Pharmaceuticals Sees Relative Strength Rating Jump To 92", "Stocks With Rising Relative Strength: Amgen", "Aerie Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Threshold", "Global Blood Therapeutic Earns Relative Strength Rating Upgrade", "Stocks With Rising Relative Strength: Intra-Cellular Therapies", "Ionis Pharmaceuticals Clears Technical Benchmark, Hitting 80-Plus RS Rating", "Stocks With Rising Relative Price Strength: Innoviva", "Stocks With Rising Relative Price Strength: Innoviva", "Stocks To Watch: Adamas Pharmaceuticals Sees Relative Strength Rating Jump To 92", "Stocks With Rising Relative Strength: Amgen", "Stocks Flashing Renewed Technical Strength: Acceleron Pharma", "Flexion Therapeutics Sees Relative Strength Rating Improve To 75", "Ionis Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark", "Clovis Oncology Scores Relative Strength Rating Upgrade", "Aerie Pharmaceuticals Sees IBD RS Rating Climb To 73", "Stocks Showing Market Leadership: Sarepta Therapeutics Earns 91 RS Rating", "Acceleron Pharma Reaches 80-Plus Relative Strength Rating Benchmark", "Stocks Flashing Renewed Technical Strength: Innoviva", "3 Bargain Biotech Stocks You Can Buy Today", "Global Blood Therapeutic Clears Technical Benchmark, Hitting 80-Plus RS Rating", "Acceleron Pharma Trying To Close In On Key Technical Measure", "Acorda Therapeutics Getting Closer To Key Technical Measure", "Stocks To Watch: Prothena Sees Relative Strength Rating Jump To 81", "3 Highest-Growth Stocks in the Market Today", "Interesting CORT Put And Call Options For May 2018", "3 Stocks That Have Doubled This Year", "Pfizer's sNDA for Bosulif Accepted in the U.S. and Europe", "7 Buy-Ranked Stocks That Just Touched New All-Time Highs", "Top Ranked Momentum Stocks to Buy for August 29th", "Mylan and Otsuka Ink Agreement to Commercialize Deltyba", "CORT Crosses Above Average Analyst Target", "3 Highest-Growth Stocks in the Market Today", "Interesting CORT Put And Call Options For May 2018", "3 Stocks That Have Doubled This Year", "Pfizer's sNDA for Bosulif Accepted in the U.S. and Europe", "7 Buy-Ranked Stocks That Just Touched New All-Time Highs", "Top Ranked Momentum Stocks to Buy for August 29th", "Mylan and Otsuka Ink Agreement to Commercialize Deltyba", "CORT Crosses Above Average Analyst Target", "BioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End", "Lannett (LCI) Q4 Earnings In Line, Stock Up on Solid View", "Three Stocks Breaking Out", "What's a Retailer To Do?", "Why Corcept Therapeutics (CORT) Could Be Positioned for a Surge", "Can The Uptrend Continue for Corcept Therapeutics (CORT)?", "Top Ranked Momentum Stocks to Buy for August 7th", "Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars", "Corcept (CORT) Q2 Earnings Beat Estimates, Guidance Raised", "Why Corcept Therapeutics Incorporated Stock Surged Higher Today", "Health Care Sector Update for 08/02/2017: CORT,ONCE,COTV", "CORT Crosses Above Average Analyst Target", "Ingalls & Snyder Llc Buys General Electric Co, Delta Air Lines Inc, JPMorgan Chase, Sells ...", "3 Under-the-Radar Stocks in the Healthcare Sector", "Vertex (VRTX) Triple Combination CF Studies Data Positive", "Corcept (CORT) Looks Good: Stock Moves Up 8.8% in Session", "Corcept Therapeutics Focuses on Korlym's Label Expansion", "Why is Corcept's Stock Up More Than 60% So Far This Year?", "Corcept Therapeutics Incorporated in 3 Charts", "Plains GP Holdings LP (PAGP) and Green Plains Inc (GPRE) Lead Today\u2019s Top 11 Investor Filings", "Health Care Sector Update for 03/06/2017: CORT,TGTX,IONS", "Health Care Sector Update for 01/31/2017: CORT,AEZS,TENX", "3 Stocks Expected to More Than Double Their Earnings in 2017", "7 Healthcare Stocks With A-Rated Prospects", "Nivalis' (NVLS) Shares Down After Merger Deal with Alpine", "AMAG Files for FDA Approval of Subcutaneous Form of Makena", "Corcept (CORT) Up 18% Since Earnings Report: Can It Continue?", "Corcept (CORT) Strives to Commercialize Key Drug Korlym", "Top 3 Growth Stocks Under $10", "Ionis/Biogen Complete Nusinersen NDA Submission in U.S.", "PAREXEL International (PRXL) Set to Acquire ExecuPharm", "Mid-Day Market Update: Conatus Jumps Following Announcement of Licensing Deal With Novartis; Sucampo Shares Slide", "Novartis Ilaris Approved for Extended Use in Periodic Fever", "Glaxo/J&J File BLA for Rheumatoid Arthritis Drug in the U.S.", "Edwards Lifesciences, DaVita HealthCare Partners, Corcept Therapeutics and CryoLife highlighted as Zacks Bull and Bear of the Day", "Adamas (ADMS) Parkinson's Disease Drug Positive in Phase III", "Aldeyra Therapeutics (ALDX) Worth a Look: Stock Gains 7%", "New Strong Buy Stocks for September 21st", "Here are 2 Momentous Healthcare Stocks to Buy Now", "Array (ARRY) Hits 52-Week High on Positive Phase III Data", "Novartis (NVS) Presents Positive Data on Cardiovascular Drug", "Advanced Accelerator (AAAP) Worth Watching: Stock Jumps 6.2%", "Should You Get Rid of Forward Pharma (FWP) Now?", "Nivalis Therapeutics (NVLS) Catches Eye: Stock Jumps 5.8%", "Glaxo/J&J File for Rheumatoid Arthritis Drug Sirukumab in EU", "Geron (GERN) at 52-Week Low on Imetelstat Study Update", "Auris (EARS) Advances on Sudden Deafness Study, Stock Up", "Eli Lilly (LLY) Gets Favorable CHMP Opinion for Olaratumab", "Agios' (AGIO) Partner Celgene to File for Enasidenib, Stock Up", "GW Pharmaceuticals (GWPH) Stock Gains on Buyout Rumors", "Bristol-Myers' Orencia Gains EU Approval for Expanded Use", "BioMarin's (BMRN) Brineura Review Period Extended by FDA", "Karyopharm Reports Positive Multiple Myeloma Study Data", "Sage Therapeutics: Breakthrough Status for Depression Drug", "Novartis (NVS) Reports Positive Data on Ultibro Breezhaler", "4 Growth Stocks at Low Prices to Counter the Market Slump", "Catalyst Firdapse Gets Orphan Status for Myasthenia Gravis", "Array (ARRY) Oncology Drug Accepted for Review in the U.S.", "Bet on These 5 Profitable Stocks for Big Returns", "Roche Immuno-oncology Drug Tecentriq Positive in Phase III", "Roche Gets FDA Nod for Emergency Use of Zika Virus Test", "Novartis (NVS) Reports Positive Phase III Results on MS Drug", "Mallinckrodt to Divest Nuclear Imaging Business for $690M", "Zacks.com featured highlights: Corcept Therapeutics, Parsley Energy, TRI Pointe Group, NuVasive and Facebook", "Catalyst Firdapse Gets Orphan Status for Myasthenia Gravis", "Array (ARRY) Oncology Drug Accepted for Review in the U.S.", "Bet on These 5 Profitable Stocks for Big Returns", "Roche Immuno-oncology Drug Tecentriq Positive in Phase III", "Roche Gets FDA Nod for Emergency Use of Zika Virus Test", "What Falling Estimates & Price Mean for Merus Labs International (MSLI)", "Horizon (HZNP) Rayos Receives USPTO Notice of Allowance", "J&J (JNJ) Seeks EU Approval for Darzalex's Expanded Use", "Novartis Licenses Anti-PCSK9 Antibody to Cyon Therapeutics", "Cempra's Application for Pneumonia Drug Validated in EU", "Gilead (GILD) Truvada Gets EU Approval for Label Expansion", "Roche Launches Accu-Chek Blood Glucose Monitoring System", "Supernus' Trokendi XR Gets FDA Nod for Migraine in Adults", "What Falling Estimates & Price Mean for Merus Labs International (MSLI)", "Horizon (HZNP) Rayos Receives USPTO Notice of Allowance", "J&J (JNJ) Seeks EU Approval for Darzalex's Expanded Use", "Novartis Licenses Anti-PCSK9 Antibody to Cyon Therapeutics", "Cempra's Application for Pneumonia Drug Validated in EU", "Gilead (GILD) Truvada Gets EU Approval for Label Expansion", "Roche Launches Accu-Chek Blood Glucose Monitoring System", "Supernus' Trokendi XR Gets FDA Nod for Migraine in Adults", "What Falling Estimates & Price Mean for Merus Labs International (MSLI)", "Horizon (HZNP) Rayos Receives USPTO Notice of Allowance", "J&J (JNJ) Seeks EU Approval for Darzalex's Expanded Use", "Insys Therapeutics Starts Enrollment in Cannabidiol Trial", "Glaxo/Pfizer ViiV Healthcare Starts HIV Drug Combo Study", "OncoGenex Down on Poor Phase III Data on Lead Cancer Drug", "Aurinia (AUPH) Stock Falls on Poor Phase II Lupus Study Data", "Endo (ENDP) Withdraws Label Expansion Filing for Opana ER", "GW Pharma (GWPH) Incurs Narrower-than-Expected Q3 Loss", "Inovio (INO) Q2 Loss in Line with Estimates, Revenues Top", "Adverum (ADVM) Reports Narrower-than-Expected Q2 Loss", "Why Corcept Therapeutics (CORT) Could Be a Potential Winner", "Endocyte (ECYT) Q2 Loss Wider than Expected (Revised)", "Horizon (HZNP) Earnings Up Y/Y, Keeps '16 View, Stock Up", "Zacks.com featured highlights: Logitech International SA, A10 Networks, TriNet Group, Corcept Therapeutics and Antero Resources", "Corcept (CORT) Reports Early Breast Cancer Data on Korlym", "Wednesday 5/11 Insider Buying Report: CORT, NEWM", "5 Liquid Stocks for a Steady Flow of High Returns", "Corcept Therapeutics Rose 18% in March. Here's Why.", "Corcept Therapeutics (CORT) Jumps: Stock Moves Up 9.6%", "The Zacks Analyst Blog Highlights: Corcept Therapeutics, Epizyme, Geron and Synthetic Biologics", "Galmed Pharmaceuticals (GLMD) Jumps: Stock Rises 7.9%", "Valeant CEO Gets Subpoena from Senate Aging Committee", "Aerie Starts Dosing in Registration Trial Mercury 2 on Roclatan", "4 Surging Stocks Brokers Love in the Healthcare Sector", "Corcept (CORT) Posts In-Line Q1 Earnings, Korlym in Focus", "Can The Uptrend Continue for Corcept Therapeutics (CORT)?", "Valeant to Get a New CEO Amid Turmoil, Ackman on Board", "Valeant Pharmaceuticals (VRX) Jumps: Stock Adds 7.4%", "McKesson (MCK) to Restructure Operations, Lower Headcount", "Walgreens Buys AmerisourceBergen Shares per Warrants", "UCB and Amgen Report Positive Data on Osteoporosis Drug", "The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Corcept Therapeutics, Sucampo Pharmaceuticals and Actelion", "Roche Files for FDA Approval of Elecsys BRAHMS Assay", "Bio Blast Pharma (ORPN) in Focus: Stock Moves Up 54.5%", "Valeant Pharmaceuticals (VRX) in Focus after Epic Decline", "3 Hedge Funds That Lost Hundreds of Millions on Valeant Stock", "Valeant Trims View, Likely to Face Credit Default; Shares Fall", "Catalyst (CPRX) Posts In-Line Q4 Loss, FDA Meeting in Focus", "Forward Pharma (FWP) Jumps: Stock Adds 23.1% in Session", "Immune Design Loss Wider than Expected, Pipeline in Focus", "Forget Valeant, Buy These 5 Drug Stocks Instead", "Radius Health (RDUS) Jumps: Stock Adds 15.5% in Session", "Valeant Terminates Litigation with R&O Pharmacy", "Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q4", "McKesson to Buy Canadian Pharmacy Chain Rexall Health", "Corcept's (CORT) Q4 Earnings Impress, Pipeline in Focus", "Aerie (AERI) Q4 Loss Wider than Expected, Pipeline in Focus", "Concert's Early-Stage Cystic Fibrosis Drug Shows Promise", "Allergan's Prior Approval Supplement for Restasis Gets CRL", "Novo Nordisk Presents Data on Tresiba and Semaglutide", "Aerie (AERI) Reports Positive Interim Results on Rhopressa", "Catalyst (CPRX) Down on FDA's Refusal to File Firdapse NDA", "Intercept Pharmaceuticals (ICPT) Soars on Buyout Rumors", "Catalyst (CPRX) Initiates Study on Firdapse for MuSK-MG", "Shire's NDA Resubmission for Lifitegrast Accepted by FDA", "AmerisourceBergen Beats on Q1 Earnings, Narrows Outlook", "Pacira Slips to Q4 Loss, Misses Estimates; Exparel in Focus", "Genocea Doses Patients in Phase IIb Study on GEN-003", "Quality Systems Beats Q3 Earnings, Lags Revenue Estimates", "Corcept Reports Preliminary Q4 Earnings, Revenues in Line", "Abbott Labs (ABT) Beats on Q4 Earnings, Lags on Revenues", "Radius (RDUS) Collaborates With Novartis Targeting Cancer", "OncoGenex Cancer Drug Fails to Show PFS in Phase II Trial", "Roche/AbbVie's Leukemia Drug Gets Breakthrough Status", "Conatus Up on Fast Track Status for Emricasan in the U.S.", "Intellipharmaceutics Up on Positive Rexista Oxycodone Data", "Gilead Seeks Approval for Tenofovir Alafenamide for HBV", "Immune Design's Immunotherapy Drugs Get Orphan Status", "Cempra Slumps: CEMP Falls 10.5% in Session", "Teva (TEVA) and Checkpoint Therapeutics Ink Oncology Deal", "Conatus (CNAT) Reports Positive Phase II Data on Emricasan", "Auris Medical (EARS) Catches Eye: Stock Moves Up 16.9%", "Novartis Gets FDA Nod for Label Expansion of Cosentyx", "Baxalta (BXLT) Inks Immuno-Oncology Deal with Symphogen", "KemPharm Expands Pipeline to Include Pain Candidate KP746", "Minerva (NERV) Looks Good: Stock Moves 6.8% Higher", "VIVUS to Regain U.S. and Canada Stendra Rights from Endo", "Minerva's Schizophrenia Drug Application Accepted by FDA", "Chimerix (CMRX) Tanks on Disappointing Brincidofovir Data", "Kamada (KMDA) Reports Encouraging Data on Rabies Drug", "Gilead Up on Encouraging Data on Tenofovir Alafenamide", "Mid-Morning Market Update: Markets Edge Lower; Cal-Maine Misses Q2 Expectations", "Adamas (ADMS) Surges on Positive Data on Lead Candidate", "Celyad's C-Cure IND Authorized in U.S. for Phase III Study", "Celgene (CELG) Settles Revlimid Patent Litigation with Natco", "Achaogen (AKAO) Catches Eye: Stock Adds 6.4% in Session", "Ohr Pharmaceutical (OHRP) Worth Watching: Stock Up 10.5%", "AVEO Licenses Tivozanib European Rights to EUSA Pharma", "GW Pharmaceuticals Publishes Encouraging Epidiolex Data", "Mid-Morning Market Update: Markets Edge Lower; Cal-Maine Misses Q2 Expectations", "Adamas (ADMS) Surges on Positive Data on Lead Candidate", "Valeant Slashes View for Q4 and 2015, Issues 2016 Outlook", "Zoetis (ZTS) Declares 14.5% Hike in Quarterly Dividend", "Clovis (CLVS) Rociletinib's Review Period Extended by FDA", "Bristol-Myers/Neon Therapeutics Ink Immuno-Oncology Deal", "Valeant in Price Cut Deal with Walgreens: Will Investors Gain?", "BioMarin's (BMRN) Kyndrisa Review Period Extended by FDA", "Akebia Up on Mitsubishi Tanabe Pharma Deal for Vadadustat", "Aduro's CRS-207/GVAX Pancreas Gets Orphan Status in EU", "Atara Plunges on Poor Results from Phase II PINTA 745 Study", "Pacira Resolves Litigation Related to Exparel with the FDA", "Corcept Releases Initial Data on Korlym/Halaven Combination", "Roche's Alecensa Approved in the U.S. for Lung Cancer", "Otonomy's Ear Infection Drug Otiprio Approved in the U.S.", "Evotec/Spero Deal Extended For Gram-negative Bacteria", "Auris Medical (EARS) Shows Strength: Stock Rises 22.4%", "Sanofi's Dengue Vaccine Dengvaxia Gets Mexican Approval", "OncoGenex to Continue with Borealis-2 Study on Apatorsen", "MEI Pharma (MEIP) Worth Watching: Stock Gains 5.4%", "How Corcept Therapeutics (CORT) Stock Stands Out in a Strong Industry", "Progenics (PGNX) Reaches Target Enrolment in Azedra Study", "Cytori Reports Positive Top-Line Data on ECCS-50 Yet Again", "Raptor Reports Efficacy Data from CYST-HD Study on RP103", "BioLineRx (BLRX) Worth Watching: Stock Rises 11.3%", "Celyad Starts 2nd Cohort of Phase I on NKG2D CAR T-Cell", "Affimed (AFMD) Shows Strength: Stock Moves 6.7% Higher", "Mallinckrodt (MNK) Sells Contrast Media & Delivery Systems", "Merck KGaA-Pfizer's Avelumab May Get Orphan Status in EU", "Ocular Begins Second Phase III Allergic Conjunctivitis Study", "BioMarin's Vimizim Gets NICE Recommendation in England", "Zafgen Sinks on 2nd Death in Obesity Study, Full Clinical Hold", "SurModics Buys Balloon Catheter Maker Creagh Medical", "Merus Labs International (MSLI) Jumps: Stock Rises 6.4%", "Ohr Pharmaceutical (OHRP) Jumps: Stock Moves 8.1% Higher", "Aduro (ADRO) Creates Subsidiary, Aduro Biotech Europe", "David Swensen's Transactions Show Diversity of Portfolio", "Earnings Estimates Moving Higher for Corcept Therapeutics (CORT): Time to Buy?", "AMAG Receives Another CRL for Single-Dose Vial of Makena", "AMAG Responds to FDA's CRL for Single-Dose Vial of Makena", "Strength Seen in FibroGen (FGEN): Stock Rises 6.3%", "ArQule's Drug Gets Orphan Drug Status for Proteus Syndrome", "Radius Health Seeks Approval for Abaloparatide-SC in EU", "Is Corcept Therapeutics an Incredible Momentum Stock? 3 Reasons Why CORT Will Be Tough to Beat", "Immune Design Posts Narrower-Than-Expected Loss for Q3", "SurModics (SRDX) Q4 Earnings, Revenues Beat Estimates", "Otonomy (OTIC) Shows Strength: Stock Moves Up 13.7%", "Spectrum (SPPI) Up on Selling Zevalin Rights to Mundipharma", "Immune Design Starts Mid-Stage Soft Tissue Sarcoma Trial", "Can the Rally in Corcept Therapeutics (CORT) Shares Continue?", "Catalyst Pharmaceuticals' Q3 Loss Narrower than Expected", "Inovio's (INO) Q3 Earnings Impress, Revenues Up Y/Y", "Avalanche (AAVL) Reports Wider-than-Expected Loss in Q3", "Seattle Genetics' (SGEN) Loss Widens Y/Y, Outlook Upped", "Novo Nordisk (NVO) Beats on Q3 Earnings, Maintains View", "Alnylam (ALNY) Reports Positive Interim Data on ALN-PCSsc", "Immune Design Starts Mid-Stage Soft Tissue Sarcoma Trial", "Merck KGaA/Pfizer's Avelumab Gets Fast Track Status", "Merck KGaA's Pipeline on Track, Updates Key R&D Projects", "Novavax's Respiratory Vaccine Study Data Fail to Impress", "Why Valeant's (VRX) Shares Plummeted in Monday Trading", "Shire's (SHPG) Vyvanse U.S. Patent Validated, Expiry in 2023", "OncoGenex Down on Failure of Pancreatic Cancer Study", "Dr. Reddy's (RDY) Q2 Earnings Rise Y/Y, Biosimilars in Focus", "Vertex (VRTX) Provides Updates on Cystic Fibrosis Pipeline", "AmerisourceBergen Launches $2.4B Share Buyback Program", "Shire's Non-Stimulant Intuniv Approved in Europe for ADHD", "MediWound (MDWD) Looks Good: Stock Jumps 6%", "Merck KGaA Continues Restructuring Efforts, Growth in Focus", "New Strong Buy Stocks for September 16th", "New Strong Buy Stocks for September 11th", "Ampio (AMPE) Starts Final Phase III Study on Knee Pain Drug", "Pacira Files Lawsuit vs. FDA Over Exparel Marketing", "Endocyte Reveals Overall Survival Data from TARGET Study", "New Strong Buy Stocks for September 8th", "Others Overlooked Corcept Therapeutics (CORT), Should You Buy It Now?", "Juniper Pharmaceuticals (JNP) Rises: Stock Jumps 5.6%", "Novartis (NVS) Launches Zarxio: First Biosimilar in the U.S.", "Collegium Pharmaceutical (COLL) in Focus: Stock Tumbles 14%", "Tetraphase's (TTPH) Antibiotic Fails in Phase III Study", "Bristol-Myers to Pay up to $1.25B for Right to Buy Promedior", "Corcept Therapeutics (CORT) Jumps: Stock Moves Up 10.9%", "Lannett Company (LCI) in Focus: Stock Moves 7.4% Higher", "Sucampo to Acquire R-Tech Ueno for About $278 Million", "Why Bellicum Pharmaceuticals (BLCM) Could Be Positioned for a Slump", "Shire Inks Deal with Sanquin to Expand Cinryze Production", "Bear of the Day: Jazz Pharma (JAZZ)", "New Strong Buy Stocks for September 1st", "Roche to Buy Kapa Biosystems, Boost Diagnostics Business", "New Strong Buy Stocks for August 20th", "Corcept Therapeutics (CORT): An Off-the-Radar Potential Winner", "Immune Design's Q2 Loss Narrows Y/Y, Focus on Pipeline", "Bristol-Myers' Cancer Drug Opdivo FDA Action Date Delayed", "Catalyst Pharmaceuticals' Loss Wider Y/Y, Firdapse in Focus - Analyst Blog", "Merrimack Pharmaceuticals' Q2 Loss Wider, Revenues Up - Analyst Blog", "Is Valeant's (VRX) $1B Buy of Addyi Maker a Prudent Move?", "Roche to Buy Kapa Biosystems, Boost Diagnostics Business", "New Strong Buy Stocks for August 20th", "Orexigen 2Q Loss Wider Than Expected, Settles with Takeda - Analyst Blog", "Merck KGaA's Net Income Up Y/Y, 2015 View Retained - Analyst Blog", "Medivation Tops Q2 Earnings & Ups View, Xtandi Impresses - Analyst Blog", "Corcept's Q2 Loss Narrower than Expected, View Narrowed - Analyst Blog", "Roche Earnings Down Y/Y, Oncology/Immunology Drive Sales - Analyst Blog", "Mallinckrodt to Acquire Therakos, Boost Hospital Business", "Valeant (VRX) Beats on Q2 Earnings & Revenues, Ups View - Analyst Blog", "Mid-Day Market Update: Dow Dips Over 1%; Harley-Davidson Shares Rise On Earnings Beat", "Corcept Therapeutics' Korlym Positive in Breast Cancer Study - Analyst Blog", "Corcept Therapeutics Reports Wider Q1 Loss, Revenue Miss - Analyst Blog", "3 Soaring Biotech Stocks Under $10 -- Are They Buys?", "Health Care Sector Update for 04/21/2015: SNTA, CORT, GNCA", "Corcept Therapeutics (CORT) Looks Good: Stock Up 83.9% - Tale of the Tape", "Shire's (SHPG) Q2 Earnings Lag Estimates, 2015 View Raised - Analyst Blog", "Valeant (VRX) Beats on Q2 Earnings & Revenues, Ups View - Analyst Blog", "Will Corcept (CORT) Continue to Surge Higher? - Tale of the Tape", "Moving Average Crossover Alert: Corcept Therapeutics (CORT) - Tale of the Tape", "Esperion Therapeutics Slumps: ESPR Falls 6.3% in Session - Tale of the Tape", "PTC Therapeutics (PTCT) Crumbles: Stock Falls by 5.5% - Tale of the Tape", "Sector Update: Health Care Stocks See Modest Declines", "Corcept's Warrants Exercised, Invest in Korlym, Pipeline - Analyst Blog", "Corcept Therapeutics (CORT) Jumps: Stock Rises 14.5% - Tale of the Tape", "Corcept Therapeutics, Inc. (CORT): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report", "Will Corcept (CORT) Continue to Surge Higher? - Tale of the Tape", "Moving Average Crossover Alert: Corcept Therapeutics (CORT) - Tale of the Tape", "Esperion Therapeutics Slumps: ESPR Falls 6.3% in Session - Tale of the Tape", "Pipeline Progress at Corcept - Analyst Blog", "Sector Update: Health Care", "Corcept Therapeutics (CORT) in Focus: Stock Rises 5.8% - Tale of the Tape", "Corcept Plunges on Study Results - Analyst Blog", "Corcept Therapeutics (CORT): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape", "Corcept Therapeutics (CORT) Jumps: Stock Adds 5.4% in Session - Tale of the Tape", "Corcept's Loss Narrows in 4Q - Analyst Blog", "Corcept Provides 4Q & 2012 Outlook - Analyst Blog", "Company News for February 22, 2012 - Corporate Summary", "Narrower-than-Expected Loss at Corcept - Analyst Blog", "The Top 20 Most Undervalued Healthcare Stocks By Target Price", "Regeneron Wins FDA Approval for Eye Drug: 3 Companies Up For Approval"], "Elapsed Time": ["5 DAYS AGO", "JUN 11, 2020", "JUN 5, 2020", "MAY 26, 2020", "MAY 12, 2020", "MAY 8, 2020", "MAY 5, 2020", "MAY 5, 2020", "5 DAYS AGO", "FEB 20, 2020", "FEB 16, 2020", "FEB 4, 2020", "JAN 24, 2020", "DEC 27, 2019", "DEC 24, 2019", "NOV 21, 2019", "FEB 26, 2020", "NOV 13, 2019", "NOV 7, 2019", "OCT 18, 2019", "OCT 15, 2019", "SEP 4, 2019", "AUG 3, 2019", "JUN 26, 2019", "NOV 20, 2019", "MAR 27, 2019", "MAR 11, 2019", "FEB 26, 2019", "FEB 26, 2019", "FEB 25, 2019", "FEB 8, 2019", "FEB 1, 2019", "MAY 10, 2019", "JAN 25, 2019", "JAN 24, 2019", "JAN 16, 2019", "JAN 14, 2019", "DEC 12, 2018", "DEC 12, 2018", "DEC 12, 2018", "JAN 28, 2019", "DEC 11, 2018", "DEC 11, 2018", "NOV 20, 2018", "NOV 5, 2018", "NOV 1, 2018", "OCT 26, 2018", "SEP 12, 2018", "DEC 12, 2018", "AUG 17, 2018", "AUG 10, 2018", "AUG 10, 2018", "AUG 9, 2018", "AUG 9, 2018", "AUG 1, 2018", "JUL 7, 2018", "AUG 20, 2018", "AUG 17, 2018", "AUG 10, 2018", "AUG 10, 2018", "AUG 9, 2018", "APR 3, 2018", "MAR 26, 2018", "MAR 18, 2018", "JUN 29, 2018", "MAR 8, 2018", "MAR 8, 2018", "FEB 23, 2018", "FEB 18, 2018", "FEB 13, 2018", "FEB 8, 2018", "FEB 5, 2018", "MAR 12, 2018", "MAR 8, 2018", "MAR 8, 2018", "FEB 23, 2018", "FEB 1, 2018", "FEB 1, 2018", "FEB 1, 2018", "JAN 26, 2018", "FEB 5, 2018", "FEB 5, 2018", "FEB 2, 2018", "JAN 26, 2018", "JAN 25, 2018", "JAN 25, 2018", "JAN 24, 2018", "JAN 24, 2018", "JAN 26, 2018", "JAN 24, 2018", "JAN 24, 2018", "JAN 24, 2018", "JAN 23, 2018", "JAN 23, 2018", "JAN 23, 2018", "JAN 23, 2018", "JAN 24, 2018", "JAN 23, 2018", "JAN 22, 2018", "JAN 22, 2018", "JAN 19, 2018", "JAN 18, 2018", "JAN 16, 2018", "JAN 16, 2018", "JAN 23, 2018", "JAN 23, 2018", "JAN 22, 2018", "JAN 22, 2018", "JAN 11, 2018", "JAN 11, 2018", "JAN 11, 2018", "JAN 11, 2018", "JAN 12, 2018", "JAN 10, 2018", "JAN 10, 2018", "JAN 9, 2018", "JAN 9, 2018", "JAN 8, 2018", "JAN 8, 2018", "JAN 3, 2018", "JAN 10, 2018", "JAN 10, 2018", "JAN 3, 2018", "JAN 3, 2018", "DEC 29, 2017", "DEC 29, 2017", "DEC 29, 2017", "JAN 3, 2018", "JAN 3, 2018", "JAN 3, 2018", "JAN 3, 2018", "JAN 3, 2018", "DEC 27, 2017", "DEC 27, 2017", "DEC 27, 2017", "DEC 28, 2017", "DEC 26, 2017", "DEC 26, 2017", "DEC 26, 2017", "DEC 26, 2017", "DEC 26, 2017", "DEC 26, 2017", "DEC 26, 2017", "DEC 27, 2017", "DEC 26, 2017", "DEC 26, 2017", "DEC 26, 2017", "DEC 26, 2017", "DEC 26, 2017", "DEC 26, 2017", "DEC 22, 2017", "DEC 22, 2017", "DEC 22, 2017", "DEC 18, 2017", "DEC 15, 2017", "DEC 15, 2017", "DEC 15, 2017", "DEC 19, 2017", "DEC 19, 2017", "DEC 14, 2017", "DEC 14, 2017", "DEC 13, 2017", "DEC 13, 2017", "DEC 13, 2017", "DEC 13, 2017", "DEC 14, 2017", "DEC 13, 2017", "DEC 12, 2017", "DEC 12, 2017", "DEC 12, 2017", "DEC 12, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 13, 2017", "DEC 13, 2017", "DEC 12, 2017", "DEC 12, 2017", "DEC 12, 2017", "DEC 12, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 13, 2017", "DEC 13, 2017", "DEC 12, 2017", "DEC 12, 2017", "DEC 12, 2017", "DEC 12, 2017", "DEC 6, 2017", "DEC 6, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 8, 2017", "DEC 7, 2017", "DEC 7, 2017", "DEC 7, 2017", "DEC 6, 2017", "DEC 6, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 8, 2017", "DEC 7, 2017", "DEC 7, 2017", "DEC 7, 2017", "DEC 6, 2017", "DEC 6, 2017", "DEC 11, 2017", "DEC 6, 2017", "DEC 5, 2017", "DEC 5, 2017", "DEC 5, 2017", "DEC 5, 2017", "DEC 4, 2017", "DEC 4, 2017", "DEC 1, 2017", "NOV 22, 2017", "NOV 20, 2017", "NOV 17, 2017", "NOV 16, 2017", "NOV 16, 2017", "NOV 16, 2017", "NOV 16, 2017", "NOV 20, 2017", "NOV 15, 2017", "NOV 15, 2017", "NOV 15, 2017", "NOV 15, 2017", "NOV 14, 2017", "NOV 14, 2017", "NOV 14, 2017", "NOV 15, 2017", "NOV 10, 2017", "NOV 10, 2017", "NOV 9, 2017", "NOV 9, 2017", "NOV 8, 2017", "NOV 6, 2017", "NOV 6, 2017", "NOV 14, 2017", "NOV 3, 2017", "NOV 3, 2017", "NOV 3, 2017", "NOV 3, 2017", "NOV 3, 2017", "NOV 2, 2017", "NOV 2, 2017", "NOV 6, 2017", "OCT 31, 2017", "OCT 31, 2017", "OCT 31, 2017", "OCT 30, 2017", "OCT 30, 2017", "OCT 30, 2017", "OCT 26, 2017", "OCT 31, 2017", "OCT 24, 2017", "OCT 20, 2017", "OCT 20, 2017", "OCT 17, 2017", "OCT 17, 2017", "OCT 16, 2017", "OCT 12, 2017", "OCT 24, 2017", "OCT 12, 2017", "OCT 11, 2017", "OCT 11, 2017", "OCT 10, 2017", "OCT 9, 2017", "OCT 6, 2017", "OCT 6, 2017", "OCT 12, 2017", "OCT 6, 2017", "OCT 5, 2017", "OCT 5, 2017", "OCT 5, 2017", "OCT 5, 2017", "OCT 3, 2017", "OCT 3, 2017", "OCT 6, 2017", "OCT 6, 2017", "OCT 5, 2017", "SEP 29, 2017", "SEP 29, 2017", "SEP 29, 2017", "SEP 28, 2017", "OCT 3, 2017", "SEP 27, 2017", "SEP 27, 2017", "SEP 27, 2017", "SEP 26, 2017", "SEP 26, 2017", "SEP 26, 2017", "SEP 26, 2017", "SEP 27, 2017", "SEP 25, 2017", "SEP 20, 2017", "SEP 14, 2017", "AUG 30, 2017", "AUG 30, 2017", "AUG 29, 2017", "AUG 25, 2017", "SEP 25, 2017", "SEP 25, 2017", "SEP 20, 2017", "SEP 14, 2017", "AUG 30, 2017", "AUG 30, 2017", "AUG 29, 2017", "AUG 25, 2017", "SEP 25, 2017", "AUG 24, 2017", "AUG 24, 2017", "AUG 16, 2017", "AUG 16, 2017", "AUG 14, 2017", "AUG 9, 2017", "AUG 7, 2017", "AUG 25, 2017", "AUG 2, 2017", "AUG 2, 2017", "AUG 2, 2017", "AUG 1, 2017", "JUL 28, 2017", "JUL 26, 2017", "JUL 19, 2017", "AUG 3, 2017", "JUL 13, 2017", "JUL 3, 2017", "JUN 26, 2017", "MAR 29, 2017", "MAR 6, 2017", "JAN 31, 2017", "JAN 8, 2017", "APR 21, 2017", "APR 20, 2017", "APR 18, 2017", "APR 6, 2017", "OCT 3, 2016", "SEP 29, 2016", "SEP 27, 2016", "SEP 27, 2016", "DEC 20, 2016", "SEP 26, 2016", "SEP 26, 2016", "SEP 22, 2016", "SEP 21, 2016", "SEP 21, 2016", "SEP 21, 2016", "SEP 21, 2016", "SEP 27, 2016", "SEP 19, 2016", "SEP 19, 2016", "SEP 14, 2016", "SEP 14, 2016", "SEP 13, 2016", "SEP 13, 2016", "SEP 12, 2016", "SEP 19, 2016", "SEP 8, 2016", "SEP 8, 2016", "SEP 7, 2016", "SEP 7, 2016", "SEP 7, 2016", "SEP 7, 2016", "SEP 6, 2016", "SEP 12, 2016", "SEP 6, 2016", "SEP 2, 2016", "SEP 2, 2016", "SEP 1, 2016", "AUG 29, 2016", "AUG 26, 2016", "AUG 25, 2016", "SEP 6, 2016", "SEP 6, 2016", "SEP 2, 2016", "SEP 2, 2016", "SEP 1, 2016", "AUG 29, 2016", "AUG 22, 2016", "AUG 19, 2016", "AUG 24, 2016", "AUG 24, 2016", "AUG 24, 2016", "AUG 23, 2016", "AUG 23, 2016", "AUG 22, 2016", "AUG 22, 2016", "AUG 19, 2016", "AUG 24, 2016", "AUG 24, 2016", "AUG 24, 2016", "AUG 23, 2016", "AUG 23, 2016", "AUG 22, 2016", "AUG 22, 2016", "AUG 19, 2016", "AUG 24, 2016", "AUG 19, 2016", "AUG 17, 2016", "AUG 17, 2016", "AUG 16, 2016", "AUG 10, 2016", "AUG 10, 2016", "AUG 9, 2016", "AUG 11, 2016", "AUG 9, 2016", "AUG 9, 2016", "AUG 9, 2016", "AUG 8, 2016", "JUN 3, 2016", "MAY 11, 2016", "AUG 5, 2016", "APR 6, 2016", "APR 1, 2016", "MAR 29, 2016", "MAR 29, 2016", "MAR 29, 2016", "MAR 29, 2016", "MAR 28, 2016", "MAY 4, 2016", "MAR 23, 2016", "MAR 22, 2016", "MAR 22, 2016", "MAR 21, 2016", "MAR 21, 2016", "MAR 21, 2016", "MAR 18, 2016", "MAR 24, 2016", "MAR 17, 2016", "MAR 17, 2016", "MAR 17, 2016", "MAR 16, 2016", "MAR 16, 2016", "MAR 15, 2016", "MAR 11, 2016", "MAR 17, 2016", "MAR 10, 2016", "MAR 10, 2016", "MAR 3, 2016", "MAR 3, 2016", "MAR 2, 2016", "MAR 2, 2016", "MAR 1, 2016", "MAR 11, 2016", "FEB 24, 2016", "FEB 18, 2016", "FEB 18, 2016", "FEB 16, 2016", "FEB 9, 2016", "FEB 5, 2016", "FEB 4, 2016", "FEB 29, 2016", "FEB 1, 2016", "JAN 29, 2016", "JAN 29, 2016", "JAN 28, 2016", "JAN 28, 2016", "JAN 21, 2016", "JAN 21, 2016", "FEB 4, 2016", "JAN 15, 2016", "JAN 13, 2016", "JAN 11, 2016", "JAN 8, 2016", "JAN 8, 2016", "JAN 7, 2016", "JAN 6, 2016", "JAN 18, 2016", "JAN 5, 2016", "JAN 4, 2016", "JAN 4, 2016", "JAN 4, 2016", "DEC 30, 2015", "DEC 29, 2015", "DEC 29, 2015", "JAN 6, 2016", "DEC 24, 2015", "DEC 24, 2015", "DEC 23, 2015", "DEC 23, 2015", "DEC 22, 2015", "DEC 22, 2015", "DEC 22, 2015", "DEC 28, 2015", "DEC 24, 2015", "DEC 24, 2015", "DEC 17, 2015", "DEC 17, 2015", "DEC 16, 2015", "DEC 16, 2015", "DEC 16, 2015", "DEC 21, 2015", "DEC 15, 2015", "DEC 15, 2015", "DEC 15, 2015", "DEC 15, 2015", "DEC 15, 2015", "DEC 14, 2015", "DEC 14, 2015", "DEC 16, 2015", "DEC 10, 2015", "DEC 10, 2015", "DEC 10, 2015", "DEC 9, 2015", "DEC 7, 2015", "DEC 4, 2015", "DEC 3, 2015", "DEC 11, 2015", "DEC 2, 2015", "DEC 2, 2015", "DEC 1, 2015", "NOV 30, 2015", "NOV 27, 2015", "NOV 26, 2015", "NOV 24, 2015", "DEC 3, 2015", "NOV 23, 2015", "NOV 20, 2015", "NOV 20, 2015", "NOV 20, 2015", "NOV 19, 2015", "NOV 19, 2015", "NOV 19, 2015", "NOV 24, 2015", "NOV 18, 2015", "NOV 18, 2015", "NOV 18, 2015", "NOV 17, 2015", "NOV 13, 2015", "NOV 12, 2015", "NOV 12, 2015", "NOV 19, 2015", "NOV 12, 2015", "NOV 11, 2015", "NOV 10, 2015", "NOV 10, 2015", "NOV 10, 2015", "OCT 30, 2015", "OCT 30, 2015", "NOV 12, 2015", "NOV 12, 2015", "OCT 8, 2015", "OCT 2, 2015", "SEP 30, 2015", "SEP 29, 2015", "SEP 25, 2015", "SEP 24, 2015", "OCT 30, 2015", "OCT 9, 2015", "SEP 22, 2015", "SEP 22, 2015", "SEP 17, 2015", "SEP 16, 2015", "SEP 16, 2015", "SEP 11, 2015", "SEP 23, 2015", "SEP 9, 2015", "SEP 8, 2015", "SEP 8, 2015", "SEP 8, 2015", "SEP 3, 2015", "SEP 3, 2015", "SEP 2, 2015", "SEP 9, 2015", "SEP 1, 2015", "AUG 27, 2015", "AUG 27, 2015", "AUG 27, 2015", "AUG 26, 2015", "AUG 26, 2015", "AUG 25, 2015", "SEP 1, 2015", "AUG 20, 2015", "AUG 20, 2015", "AUG 14, 2015", "AUG 13, 2015", "AUG 13, 2015", "AUG 11, 2015", "AUG 11, 2015", "AUG 21, 2015", "AUG 20, 2015", "AUG 7, 2015", "AUG 7, 2015", "AUG 7, 2015", "AUG 7, 2015", "AUG 6, 2015", "JUL 24, 2015", "AUG 11, 2015", "JUL 24, 2015", "JUL 21, 2015", "MAY 15, 2015", "MAY 8, 2015", "APR 22, 2015", "APR 21, 2015", "APR 9, 2015", "JUL 24, 2015", "JUL 24, 2015", "DEC 15, 2014", "DEC 11, 2014", "OCT 13, 2014", "OCT 13, 2014", "AUG 6, 2014", "APR 2, 2015", "MAR 12, 2015", "DEC 31, 2014", "DEC 15, 2014", "DEC 11, 2014", "OCT 13, 2014", "DEC 16, 2013", "AUG 6, 2014", "MAY 12, 2014", "MAY 8, 2014", "APR 4, 2014", "MAY 7, 2013", "MAR 14, 2013", "FEB 15, 2013", "FEB 22, 2012", "NOV 8, 2013", "JAN 14, 2011", "DEC 3, 2011"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/first-week-of-cort-february-2021-options-trading-2020-06-22", "https://www.nasdaq.com/articles/7-great-biotech-stocks-to-buy-and-hold-now-2020-06-11", "https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-6-5-2020-2020-06-05", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity%3A-wing-cort-dis-2020-05-26", "https://www.nasdaq.com/articles/should-you-climb-on-board-the-corcept-therapeutics-train-2020-05-12", "https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-5-8-2020-2020-05-08", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-05-2020%3A-cemi-gnmk-cort-xlv-vht-iyh-2020-05-05", "https://www.nasdaq.com/articles/corcept-therapeutics-incorporated-cort-q1-2020-earnings-call-transcript-2020-05-05", "https://www.nasdaq.com/articles/first-week-of-cort-february-2021-options-trading-2020-06-22", "https://www.nasdaq.com/articles/corcept-therapeutics-incorporated-cort-q4-2019-earnings-call-transcript-2020-02-21", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-motley-fool-2-16-2020-2020-02-16", "https://www.nasdaq.com/articles/validea-motley-fool-strategy-daily-upgrade-report-2-4-2020-2020-02-04", "https://www.nasdaq.com/articles/analysts-anticipate-pjp-will-reach-%2473-2020-01-24", "https://www.nasdaq.com/articles/corcept-therapeutics-enters-oversold-territory-cort-2019-12-27", "https://www.nasdaq.com/articles/how-the-pieces-add-up%3A-pbe-targets-%2462-2019-12-24", "https://www.nasdaq.com/articles/ftxhs-holdings-could-mean-15-gain-potential-2019-11-21", "https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-2-26-2020-2020-02-26", "https://www.nasdaq.com/articles/cort-crosses-above-average-analyst-target-2019-11-13", "https://www.nasdaq.com/articles/corcept-therapeutics-incorporated-cort-q3-2019-earnings-call-transcript-2019-11-08", "https://www.nasdaq.com/articles/notable-friday-option-activity%3A-jpm-mu-cort-2019-10-18", "https://www.nasdaq.com/articles/interesting-cort-put-and-call-options-for-december-20th-2019-10-15", "https://www.nasdaq.com/articles/sum-up-the-pieces%3A-fad-could-be-worth-%2482-2019-09-04", "https://www.nasdaq.com/articles/corcept-therapeutics-incorporated-cort-q2-earnings-call-transcript-2019-08-03", "https://www.nasdaq.com/articles/first-week-of-february-2020-options-trading-for-corcept-therapeutics-cort-2019-06-26", "https://www.nasdaq.com/articles/heres-why-corcept-therapeutics-stock-hit-the-bricks-today-2019-11-20", "https://www.nasdaq.com/articles/corcept-cort-down-6.1-since-last-earnings-report%3A-can-it-rebound-2019-03-27", "https://www.nasdaq.com/articles/heres-why-corcept-therapeutics-shares-rose-115-february-2019-03-11", "https://www.nasdaq.com/articles/corcept-cort-q4-earnings-beat-estimates-revenues-in-line-2019-02-26", "https://www.nasdaq.com/articles/corcept-therapeutics-incorporated-cort-q4-2018-earnings-conference-call-transcript-2019-02", "https://www.nasdaq.com/articles/earnings-reaction-history-corcept-therapt-333-follow-through-indicator-54-sensitive-2019", "https://www.nasdaq.com/articles/options-traders-expect-huge-moves-in-corcept-cort-stock-2019-02-08", "https://www.nasdaq.com/articles/heres-why-corcept-therapeutics-fell-much-137-today-2019-02-01", "https://www.nasdaq.com/articles/corcept-therapeutics-incorporated-cort-q1-2019-earnings-call-transcript-2019-05-10", "https://www.nasdaq.com/articles/heres-why-corcept-therapeutics-stock-fell-much-185-today-2019-01-25", "https://www.nasdaq.com/articles/first-week-cort-march-15th-options-trading-2019-01-24", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-blk-algn-cort-2019-01-16", "https://www.nasdaq.com/articles/cort-crosses-above-key-moving-average-level-2019-01-14", "https://www.nasdaq.com/articles/cort-crosses-above-average-analyst-target-2018-12-12", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-cort-xpo-cost-2018-12-12", "https://www.nasdaq.com/articles/2-marijuana-stocks-among-4-charts-looking-higher-2018-12-12", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-dht-cort-expe-2019-01-28", "https://www.nasdaq.com/articles/heres-why-corcept-therapeutics-surged-today-2018-12-11", "https://www.nasdaq.com/articles/heres-why-corcept-therapeutics-rose-186-november-2018-12-11", "https://www.nasdaq.com/articles/corcept-initiates-phase-iii-study-for-cushings-syndrome-2018-11-20", "https://www.nasdaq.com/articles/corcept-cort-q3-earnings-in-line-revenues-miss-estimates-2018-11-05", "https://www.nasdaq.com/articles/corcept-therapeutics-cort-meets-q3-earnings-estimates-2018-11-01", "https://www.nasdaq.com/articles/how-pieces-add-ijt-targets-215-2018-10-26", "https://www.nasdaq.com/articles/do-options-traders-know-something-about-corcept-cort-stock-we-dont-2018-09-12", "https://www.nasdaq.com/articles/wednesdays-etf-unusual-volume-smlf-2018-12-12", "https://www.nasdaq.com/articles/friday-817-insider-buying-report-cort-cnne-2018-08-17", "https://www.nasdaq.com/articles/heres-why-corcept-therapeutics-inc-fell-much-174-today-2018-08-10", "https://www.nasdaq.com/articles/corcept-cort-earnings-and-revenues-miss-estimates-in-q2-2018-08-10", "https://www.nasdaq.com/articles/corcept-therapeutics-cort-misses-q2-earnings-and-revenue-estimates-2018-08-09", "https://www.nasdaq.com/articles/earnings-reaction-history-corcept-therapeutics-incorporated-400-follow-through-indicator", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-cort-adbe-zn-2018-08-01", "https://www.nasdaq.com/articles/validea-motley-fool-strategy-daily-upgrade-report-772018-2018-07-07", "https://www.nasdaq.com/articles/3-high-growth-stocks-could-soar-2018-08-20", "https://www.nasdaq.com/articles/friday-817-insider-buying-report-cort-cnne-2018-08-17", "https://www.nasdaq.com/articles/heres-why-corcept-therapeutics-inc-fell-much-174-today-2018-08-10", "https://www.nasdaq.com/articles/corcept-cort-earnings-and-revenues-miss-estimates-in-q2-2018-08-10", "https://www.nasdaq.com/articles/cort-crosses-above-key-moving-average-level-2018-05-02", "https://www.nasdaq.com/articles/tuesdays-etf-movers-ihe-gdxj-2018-04-03", "https://www.nasdaq.com/articles/why-is-corcept-therapeutics-cort-up-5.3-since-its-last-earnings-report-2018-03-26", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-motley-fool-3182018-2018-03-18", "https://www.nasdaq.com/articles/options-traders-expect-huge-moves-in-corcept-therapeutics-cort-stock-2018-06-29", "https://www.nasdaq.com/articles/corcept-plans-korlym-label-expansion-pipeline-in-progress-2018-03-08", "https://www.nasdaq.com/articles/corcept-therapeutics-cort-shares-cross-above-200-dma-2018-03-08", "https://www.nasdaq.com/articles/corcepts-cort-earnings-and-sales-meet-estimates-in-q4-2018-02-23", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-motley-fool-2182018-2018-02-18", "https://www.nasdaq.com/articles/why-corcept-therapeutics-stock-gained-274-january-2018-02-13", "https://www.nasdaq.com/articles/cort-crosses-below-key-moving-average-level-2018-02-08", "https://www.nasdaq.com/articles/mid-day-market-update-dow-falls-over-250-points-enphase-energy-shares-spike-higher-2018-02", "https://www.nasdaq.com/articles/why-corcept-therapeutics-incorporated-lost-34-february-2018-03-12", "https://www.nasdaq.com/articles/corcept-plans-korlym-label-expansion-pipeline-in-progress-2018-03-08", "https://www.nasdaq.com/articles/corcept-therapeutics-cort-shares-cross-above-200-dma-2018-03-08", "https://www.nasdaq.com/articles/20-best-stocks-you-probably-havent-heard-2018-02-01", "https://www.nasdaq.com/articles/la-jolla-pharmaceutical-meets-80-plus-relative-strength-rating-benchmark-2018-02-01", "https://www.nasdaq.com/articles/thursdays-etf-movers-pjp-rwr-2018-02-01", "https://www.nasdaq.com/articles/biotech-roundup-whos-popping-drug-merger-earnings-news-2018-02-01", "https://www.nasdaq.com/articles/omeros-shows-rising-price-performance-jump-81-rs-rating-2018-01-26", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-bristol-myers-profit-tops-expectations-2018", "https://www.nasdaq.com/articles/why-corcept-therapeutics-incorporated-stock-getting-clobbered-today-2018-02-05", "https://www.nasdaq.com/articles/omeros-trying-close-key-technical-measure-2018-02-02", "https://www.nasdaq.com/articles/stocks-showing-rising-market-leadership-supernus-pharmaceuticals-earns-81-rs-rating-2018", "https://www.nasdaq.com/articles/innoviva-clears-technical-benchmark-hitting-80-plus-rs-rating-2018-01-25", "https://www.nasdaq.com/articles/stocks-showing-market-leadership-concert-pharmaceuticals-earns-93-rs-rating-2018-01-25", "https://www.nasdaq.com/articles/regenxbio-earns-relative-strength-rating-upgrade-hits-key-benchmark-2018-01-24", "https://www.nasdaq.com/articles/gw-pharmaceuticals-meets-80-plus-relative-strength-rating-benchmark-2018-01-24", "https://www.nasdaq.com/articles/regenxbio-clears-technical-benchmark-hitting-80-plus-rs-rating-2018-01-26", "https://www.nasdaq.com/articles/aerie-pharmaceuticals-sees-ibd-rs-rating-improve-74-2018-01-24", "https://www.nasdaq.com/articles/stocks-rising-relative-strength-la-jolla-pharmaceutical-2018-01-24", "https://www.nasdaq.com/articles/stocks-showing-improved-relative-strength-omeros-2018-01-24", "https://www.nasdaq.com/articles/stocks-showing-improved-relative-strength-regenxbio-2018-01-23", "https://www.nasdaq.com/articles/stocks-showing-market-leadership-array-biopharma-earns-96-rs-rating-2018-01-23", "https://www.nasdaq.com/articles/bioverativ-earns-relative-strength-rating-upgrade-2018-01-23", "https://www.nasdaq.com/articles/stocks-flashing-renewed-technical-strength-exelixis-2018-01-23", "https://www.nasdaq.com/articles/alder-biopharmaceuticals-shows-rising-price-performance-jump-85-rs-rating-2018-01-24", "https://www.nasdaq.com/articles/agios-pharmaceuticals-joins-rank-stocks-rs-ratings-over-90-2018-01-23", "https://www.nasdaq.com/articles/stocks-watch-acorda-therapeutics-sees-rs-rating-jump-84-2018-01-22", "https://www.nasdaq.com/articles/ibd-rating-upgrades-innoviva-shows-improved-technical-strength-2018-01-22", "https://www.nasdaq.com/articles/10-best-stocks-president-trumps-first-year-2018-01-19", "https://www.nasdaq.com/articles/stocks-rising-relative-strength-biogen-2018-01-18", "https://www.nasdaq.com/articles/new-highs-biotech-solar-stocks-test-investor-conviction-2018-01-16", "https://www.nasdaq.com/articles/stocks-showing-market-leadership-voyager-therapeutics-earns-91-rs-rating-2018-01-16", "https://www.nasdaq.com/articles/tg-therapeutics-clears-key-benchmark-hitting-80-plus-rs-rating-2018-01-23", "https://www.nasdaq.com/articles/agios-pharmaceuticals-joins-rank-stocks-rs-ratings-over-90-2018-01-23", "https://www.nasdaq.com/articles/stocks-watch-acorda-therapeutics-sees-rs-rating-jump-84-2018-01-22", "https://www.nasdaq.com/articles/ibd-rating-upgrades-innoviva-shows-improved-technical-strength-2018-01-22", "https://www.nasdaq.com/articles/stocks-watch-halozyme-therapeutics-sees-rs-rating-rise-92-2018-01-11", "https://www.nasdaq.com/articles/alder-biopharmaceuticals-meets-80-plus-relative-strength-rating-benchmark-2018-01-11", "https://www.nasdaq.com/articles/heron-therapeutics-joins-elite-club-stocks-rs-ratings-over-90-2018-01-11", "https://www.nasdaq.com/articles/stocks-rising-relative-price-strength-regenxbio-2018-01-11", "https://www.nasdaq.com/articles/atara-biotherapeutics-joins-elite-club-stocks-rs-ratings-over-90-2018-01-12", "https://www.nasdaq.com/articles/stocks-showing-market-leadership-array-biopharma-earns-91-rs-rating-2018-01-10", "https://www.nasdaq.com/articles/portola-pharmaceuticals-reaches-80-plus-relative-strength-rating-benchmark-2018-01-10", "https://www.nasdaq.com/articles/avexis-joins-rank-stocks-rs-ratings-over-90-2018-01-09", "https://www.nasdaq.com/articles/ptc-therapeutics-clears-key-benchmark-hitting-80-plus-rs-rating-2018-01-09", "https://www.nasdaq.com/articles/stocks-showing-market-leadership-crispr-therapeutics-earns-92-rs-rating-2018-01-08", "https://www.nasdaq.com/articles/stocks-generating-improved-relative-strength-supernus-pharmaceuticals-2018-01-08", "https://www.nasdaq.com/articles/trevena-announces-fda-acceptance-of-olinvo-nda-shares-up-2018-01-03", "https://www.nasdaq.com/articles/supernus-pharmaceuticals-earns-relative-strength-rating-upgrade-hits-key-threshold-2018-01", "https://www.nasdaq.com/articles/stocks-showing-market-leadership-array-biopharma-earns-91-rs-rating-2018-01-10", "https://www.nasdaq.com/articles/ptc-therapeutics-shows-market-leadership-jump-84-rs-rating-2018-01-03", "https://www.nasdaq.com/articles/la-jolla-pharmaceutical-hits-80-plus-relative-strength-rating-benchmark-2018-01-03", "https://www.nasdaq.com/articles/therapeuticsmd-submits-nda-for-vms-candidate-shares-rise-2017-12-29", "https://www.nasdaq.com/articles/flexion-therapeutics-getting-closer-key-technical-measure-2017-12-29", "https://www.nasdaq.com/articles/supernus-pharmaceuticals-shows-rising-price-performance-jump-81-rs-rating-2017-12-29", "https://www.nasdaq.com/articles/achaogens-nda-for-plazomicin-gets-priority-review-from-fda-2018-01-03", "https://www.nasdaq.com/articles/5-reasons-to-invest-in-novo-nordisk-nvo-stock-right-now-2018-01-03", "https://www.nasdaq.com/articles/stocks-generating-improved-relative-strength-biogen-2018-01-03", "https://www.nasdaq.com/articles/ptc-therapeutics-shows-market-leadership-jump-84-rs-rating-2018-01-03", "https://www.nasdaq.com/articles/la-jolla-pharmaceutical-hits-80-plus-relative-strength-rating-benchmark-2018-01-03", "https://www.nasdaq.com/articles/why-is-corcepts-stock-up-more-than-150-so-far-this-year-2017-12-27", "https://www.nasdaq.com/articles/alexions-alxn-soliris-label-expansion-approved-in-japan-2017-12-27", "https://www.nasdaq.com/articles/innoviva-sees-rs-rating-rise-74-2017-12-27", "https://www.nasdaq.com/articles/what-drives-catalyst-pharmaceuticals-above-250-this-year-2017-12-28", "https://www.nasdaq.com/articles/mercks-diabetes-drugs-get-fda-nod-as-adjunct-therapies-2017-12-26", "https://www.nasdaq.com/articles/biomarins-bmrn-pegvaliase-review-period-extended-by-fda-2017-12-26", "https://www.nasdaq.com/articles/portolas-ptla-andexxa-bla-review-period-extended-by-fda-2017-12-26", "https://www.nasdaq.com/articles/ptc-therapeutics-clears-key-benchmark-hitting-80-plus-rs-rating-2017-12-26", "https://www.nasdaq.com/articles/stocks-showing-improving-market-leadership-voyager-therapeutics-earns-84-rs-rating-2017-12", "https://www.nasdaq.com/articles/array-biopharma-shows-rising-price-performance-jump-85-rs-rating-2017-12-26", "https://www.nasdaq.com/articles/stocks-showing-market-leadership-exelixis-earns-93-rs-rating-2017-12-26", "https://www.nasdaq.com/articles/ibd-rating-upgrades-pacira-pharmaceuticals-shows-improved-relative-price-strength-2017-12", "https://www.nasdaq.com/articles/mercks-diabetes-drugs-get-fda-nod-as-adjunct-therapies-2017-12-26", "https://www.nasdaq.com/articles/biomarins-bmrn-pegvaliase-review-period-extended-by-fda-2017-12-26", "https://www.nasdaq.com/articles/portolas-ptla-andexxa-bla-review-period-extended-by-fda-2017-12-26", "https://www.nasdaq.com/articles/ptc-therapeutics-clears-key-benchmark-hitting-80-plus-rs-rating-2017-12-26", "https://www.nasdaq.com/articles/stocks-showing-improving-market-leadership-voyager-therapeutics-earns-84-rs-rating-2017-12", "https://www.nasdaq.com/articles/array-biopharma-shows-rising-price-performance-jump-85-rs-rating-2017-12-26", "https://www.nasdaq.com/articles/strength-seen-in-corcept-therapeutics-cort%3A-stock-soars-10.8-2017-12-22", "https://www.nasdaq.com/articles/jazz-submits-nda-to-fda-for-jzp-110-to-cure-sleep-disorder-2017-12-22", "https://www.nasdaq.com/articles/corcept-therapeutics-shows-rising-price-performance-jump-95-rs-rating-2017-12-22", "https://www.nasdaq.com/articles/radius-health-to-get-third-day-180-list-of-outstanding-issues-2017-12-18", "https://www.nasdaq.com/articles/gw-pharmaceuticals-earns-relative-strength-rating-upgrade-hits-key-benchmark-2017-12-15", "https://www.nasdaq.com/articles/clovis-oncology-shows-rising-relative-strength-still-shy-key-threshold-2017-12-15", "https://www.nasdaq.com/articles/stocks-rising-relative-strength-ptc-therapeutics-2017-12-15", "https://www.nasdaq.com/articles/alnylam-sanofi-submit-maa-in-europe-for-rnai-candidate-2017-12-19", "https://www.nasdaq.com/articles/gw-pharmaceuticals-trying-close-key-technical-benchmark-2017-12-14", "https://www.nasdaq.com/articles/avexis-shows-market-leadership-jump-93-rs-rating-2017-12-14", "https://www.nasdaq.com/articles/array-biopharma-scores-relative-strength-rating-upgrade-hits-key-benchmark-2017-12-14", "https://www.nasdaq.com/articles/glaxos-nucala-label-expansion-application-gets-fda-approval-2017-12-13", "https://www.nasdaq.com/articles/proteostasis-stock-surges-on-positive-data-from-cf-studies-2017-12-13", "https://www.nasdaq.com/articles/regeneron-sanofi-report-positive-top-line-skin-cancer-data-2017-12-13", "https://www.nasdaq.com/articles/allergan-inks-deal-to-buy-texas-based-repros-therapeutics-2017-12-13", "https://www.nasdaq.com/articles/shires-new-formulation-of-oncaspar-gets-approval-in-europe-2017-12-14", "https://www.nasdaq.com/articles/stocks-showing-improving-market-leadership-pacira-pharmaceuticals-earns-81-rs-rating-2017", "https://www.nasdaq.com/articles/spark-therapeutics-stock-plunges-on-hemophilia-therapy-data-2017-12-12", "https://www.nasdaq.com/articles/mercks-keytruda-gets-fda-priority-review-for-rare-lymphoma-2017-12-12", "https://www.nasdaq.com/articles/biogen-sees-rs-rating-rise-72-2017-12-12", "https://www.nasdaq.com/articles/acceleron-pharma-sees-rs-rating-climb-74-2017-12-12", "https://www.nasdaq.com/articles/spark-therapeutics-trying-close-key-technical-benchmark-2017-12-11", "https://www.nasdaq.com/articles/stocks-generating-improved-relative-strength-supernus-pharmaceuticals-2017-12-11", "https://www.nasdaq.com/articles/stocks-showing-improved-relative-strength-supernus-pharmaceuticals-2017-12-13", "https://www.nasdaq.com/articles/stocks-showing-improving-market-leadership-pacira-pharmaceuticals-earns-81-rs-rating-2017", "https://www.nasdaq.com/articles/spark-therapeutics-stock-plunges-on-hemophilia-therapy-data-2017-12-12", "https://www.nasdaq.com/articles/mercks-keytruda-gets-fda-priority-review-for-rare-lymphoma-2017-12-12", "https://www.nasdaq.com/articles/biogen-sees-rs-rating-rise-72-2017-12-12", "https://www.nasdaq.com/articles/acceleron-pharma-sees-rs-rating-climb-74-2017-12-12", "https://www.nasdaq.com/articles/spark-therapeutics-trying-close-key-technical-benchmark-2017-12-11", "https://www.nasdaq.com/articles/stocks-generating-improved-relative-strength-supernus-pharmaceuticals-2017-12-11", "https://www.nasdaq.com/articles/stocks-showing-improved-relative-strength-supernus-pharmaceuticals-2017-12-13", "https://www.nasdaq.com/articles/stocks-showing-improving-market-leadership-pacira-pharmaceuticals-earns-81-rs-rating-2017", "https://www.nasdaq.com/articles/spark-therapeutics-stock-plunges-on-hemophilia-therapy-data-2017-12-12", "https://www.nasdaq.com/articles/mercks-keytruda-gets-fda-priority-review-for-rare-lymphoma-2017-12-12", "https://www.nasdaq.com/articles/biogen-sees-rs-rating-rise-72-2017-12-12", "https://www.nasdaq.com/articles/roche-reports-tecentriq-avastin-lung-cancer-study-data-2017-12-07", "https://www.nasdaq.com/articles/sucampo-pharmaceuticals-clears-technical-benchmark-hitting-80-plus-rs-rating-2017-12-06", "https://www.nasdaq.com/articles/spark-therapeutics-trying-close-key-technical-measure-2017-12-06", "https://www.nasdaq.com/articles/aerie-pharmaceuticals-clears-key-benchmark-hitting-80-plus-rs-rating-2017-12-11", "https://www.nasdaq.com/articles/lilly-reports-mixed-results-from-late-stage-cyramza-study-2017-12-11", "https://www.nasdaq.com/articles/pacira-pharmaceuticals-sees-rs-rating-climb-75-2017-12-08", "https://www.nasdaq.com/articles/sucampo-pharmaceuticals-earns-relative-strength-rating-upgrade-hits-key-threshold-2017-12", "https://www.nasdaq.com/articles/regenxbio-joins-rank-stocks-rs-ratings-over-90-2017-12-07", "https://www.nasdaq.com/articles/roche-reports-tecentriq-avastin-lung-cancer-study-data-2017-12-07", "https://www.nasdaq.com/articles/sucampo-pharmaceuticals-clears-technical-benchmark-hitting-80-plus-rs-rating-2017-12-06", "https://www.nasdaq.com/articles/spark-therapeutics-trying-close-key-technical-measure-2017-12-06", "https://www.nasdaq.com/articles/aerie-pharmaceuticals-clears-key-benchmark-hitting-80-plus-rs-rating-2017-12-11", "https://www.nasdaq.com/articles/lilly-reports-mixed-results-from-late-stage-cyramza-study-2017-12-11", "https://www.nasdaq.com/articles/pacira-pharmaceuticals-sees-rs-rating-climb-75-2017-12-08", "https://www.nasdaq.com/articles/sucampo-pharmaceuticals-earns-relative-strength-rating-upgrade-hits-key-threshold-2017-12", "https://www.nasdaq.com/articles/regenxbio-joins-rank-stocks-rs-ratings-over-90-2017-12-07", "https://www.nasdaq.com/articles/roche-reports-tecentriq-avastin-lung-cancer-study-data-2017-12-07", "https://www.nasdaq.com/articles/sucampo-pharmaceuticals-clears-technical-benchmark-hitting-80-plus-rs-rating-2017-12-06", "https://www.nasdaq.com/articles/spark-therapeutics-trying-close-key-technical-measure-2017-12-06", "https://www.nasdaq.com/articles/aerie-pharmaceuticals-clears-key-benchmark-hitting-80-plus-rs-rating-2017-12-11", "https://www.nasdaq.com/articles/revances-neuromodulator-injection-positive-in-phase-iii-2017-12-06", "https://www.nasdaq.com/articles/heres-why-sarepta-stock-is-up-more-than-70-in-6-months-2017-12-05", "https://www.nasdaq.com/articles/astrazenecas-copd-drug-succeeds-in-label-expansion-study-2017-12-05", "https://www.nasdaq.com/articles/ironwood-succeeds-in-diabetic-hypertension-phase-ii-study-2017-12-05", "https://www.nasdaq.com/articles/ibd-rating-upgrades-agios-pharmaceuticals-flashes-improved-relative-price-strength-2017-12", "https://www.nasdaq.com/articles/pfizer-wins-china-asia-pacific-rights-to-anti-fungal-drug-2017-12-04", "https://www.nasdaq.com/articles/glaxo-submits-nda-for-anti-relapse-malaria-medicine-to-fda-2017-11-29", "https://www.nasdaq.com/articles/bristol-myers-opdivos-lung-cancer-study-meets-early-success-2017-12-01", "https://www.nasdaq.com/articles/sage-therapeutics-shows-rising-price-performance-jump-91-rs-rating-2017-11-22", "https://www.nasdaq.com/articles/acceleron-pharma-clears-technical-benchmark-hitting-80-plus-rs-rating-2017-11-20", "https://www.nasdaq.com/articles/alnylam-starts-rolling-nda-submission-for-rnai-candidate-2017-11-17", "https://www.nasdaq.com/articles/incyte-incy-initiates-essential-thrombocythemia-trial-2017-11-16", "https://www.nasdaq.com/articles/stocks-flashing-renewed-technical-strength-regenxbio-2017-11-16", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-shows-market-leadership-jump-81-rs-rating-2017-11-16", "https://www.nasdaq.com/articles/stocks-watch-flexion-therapeutics-sees-rs-rating-jump-83-2017-11-16", "https://www.nasdaq.com/articles/exelixis-clears-technical-benchmark-hitting-80-plus-rs-rating-2017-11-20", "https://www.nasdaq.com/articles/roche-rhhby-receives-fda-clearance-for-ventana-mmr-test-2017-11-15", "https://www.nasdaq.com/articles/paciras-exparel-snda-to-be-reviewed-by-fda-advisory-committee-2017-11-15", "https://www.nasdaq.com/articles/cardinal-health-cah-to-divest-assets-to-shanghai-pharma-2017-11-15", "https://www.nasdaq.com/articles/stocks-showing-market-leadership-zynerba-pharmaceuticals-earns-91-rs-rating-2017-11-15", "https://www.nasdaq.com/articles/shire-gets-positive-chmp-opinion-for-hemophilia-a-drug-2017-11-14", "https://www.nasdaq.com/articles/alnylam-rnai-drug-gets-accelerated-assessment-grant-from-ema-2017-11-14", "https://www.nasdaq.com/articles/glaxos-subcutaneous-formulation-of-benlysta-approved-in-eu-2017-11-14", "https://www.nasdaq.com/articles/valeant-vrx-announces-pricing-of-senior-secured-notes-2017-11-15", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-micron-technology-meritor-rh-ultra-clean-holdings-and", "https://www.nasdaq.com/articles/stocks-watch-intra-cellular-therapies-sees-rs-rating-rise-88-2017-11-10", "https://www.nasdaq.com/articles/5-stocks-doubled-2017-and-can-keep-soaring-higher-2017-11-09", "https://www.nasdaq.com/articles/stocks-rising-relative-price-strength-achaogen-2017-11-09", "https://www.nasdaq.com/articles/top-rated-stocks-xoma-sees-composite-rating-climb-96-2017-11-08", "https://www.nasdaq.com/articles/emergent-biosolutions-shows-market-leadership-jump-93-rs-rating-2017-11-06", "https://www.nasdaq.com/articles/biogen-shows-rising-relative-strength-still-shy-key-threshold-2017-11-06", "https://www.nasdaq.com/articles/omeros-scores-relative-strength-rating-upgrade-hits-key-benchmark-2017-11-14", "https://www.nasdaq.com/articles/why-investors-should-be-excited-about-corcept-therapeutics-plunging-much-18-2017-11-03", "https://www.nasdaq.com/articles/acadia-pharmaceuticals-scores-relative-strength-rating-upgrade-hits-key-threshold-2017-11", "https://www.nasdaq.com/articles/stocks-showing-market-leadership-neurocrine-biosciences-earns-96-rs-rating-2017-11-03", "https://www.nasdaq.com/articles/exelixis-scores-relative-strength-rating-upgrade-2017-11-03", "https://www.nasdaq.com/articles/corcept-cort-q3-earnings-miss-estimates-guidance-raised-2017-11-03", "https://www.nasdaq.com/articles/small-cap-biotech-dips-sales-top-earnings-miss-2-cents-2017-11-02", "https://www.nasdaq.com/articles/biogen-sees-ibd-rs-rating-climb-73-2017-11-02", "https://www.nasdaq.com/articles/flexion-therapeutics-getting-closer-key-technical-measure-2017-11-06", "https://www.nasdaq.com/articles/sarepta-therapeutics-clears-key-benchmark-hitting-90-plus-rs-rating-2017-10-31", "https://www.nasdaq.com/articles/stocks-flashing-renewed-technical-strength-adamas-pharmaceuticals-2017-10-31", "https://www.nasdaq.com/articles/intra-cellular-therapies-earns-relative-strength-rating-upgrade-2017-10-31", "https://www.nasdaq.com/articles/ibd-rating-upgrades-seattle-genetics-flashes-improved-price-strength-2017-10-30", "https://www.nasdaq.com/articles/stocks-watch-adamas-pharmaceuticals-sees-relative-strength-rating-jump-82-2017-10-30", "https://www.nasdaq.com/articles/la-jolla-pharmaceutical-earns-relative-strength-rating-upgrade-2017-10-30", "https://www.nasdaq.com/articles/adamas-pharmaceuticals-clears-technical-benchmark-hitting-80-plus-rs-rating-2017-10-26", "https://www.nasdaq.com/articles/biogen-sees-relative-strength-rating-climb-75-2017-10-31", "https://www.nasdaq.com/articles/aimmune-therapeutics-scores-relative-strength-rating-upgrade-2017-10-24", "https://www.nasdaq.com/articles/innoviva-clears-key-benchmark-hitting-80-plus-rs-rating-2017-10-20", "https://www.nasdaq.com/articles/gilead-sciences-shows-rising-relative-price-performance-still-shy-key-threshold-2017-10-20", "https://www.nasdaq.com/articles/stocks-showing-market-leadership-ptc-therapeutics-earns-92-rs-rating-2017-10-17", "https://www.nasdaq.com/articles/exelixis-earns-relative-strength-rating-upgrade-2017-10-17", "https://www.nasdaq.com/articles/stocks-showing-improving-market-leadership-five-prime-therapeutics-earns-83-rs-rating-2017", "https://www.nasdaq.com/articles/intra-cellular-therapies-shows-rising-price-performance-jump-83-rs-rating-2017-10-12", "https://www.nasdaq.com/articles/3-small-profitable-biotechs-fantastic-growth-2017-10-24", "https://www.nasdaq.com/articles/aerie-pharmaceuticals-scores-relative-strength-rating-upgrade-2017-10-12", "https://www.nasdaq.com/articles/stocks-showing-rising-market-leadership-aerie-pharmaceuticals-earns-82-rs-rating-2017-10", "https://www.nasdaq.com/articles/dow-returns-all-time-highs-2017-10-11", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-wal-mart-reports-20b-buyback-plan-2017-10-10", "https://www.nasdaq.com/articles/flexion-therapeutics-clears-technical-benchmark-hitting-90-plus-rs-rating-2017-10-09", "https://www.nasdaq.com/articles/stocks-showing-improving-market-leadership-intra-cellular-therapies-earns-83-rs-rating", "https://www.nasdaq.com/articles/flexion-therapeutics-hits-80-plus-relative-strength-rating-benchmark-2017-10-06", "https://www.nasdaq.com/articles/stocks-rising-relative-price-strength-ionis-pharmaceuticals-2017-10-12", "https://www.nasdaq.com/articles/stocks-watch-adamas-pharmaceuticals-sees-relative-strength-rating-jump-92-2017-10-06", "https://www.nasdaq.com/articles/stocks-rising-relative-strength-amgen-2017-10-05", "https://www.nasdaq.com/articles/aerie-pharmaceuticals-earns-relative-strength-rating-upgrade-hits-key-threshold-2017-10-05", "https://www.nasdaq.com/articles/global-blood-therapeutic-earns-relative-strength-rating-upgrade-2017-10-05", "https://www.nasdaq.com/articles/stocks-rising-relative-strength-intra-cellular-therapies-2017-10-05", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-clears-technical-benchmark-hitting-80-plus-rs-rating-2017-10-03", "https://www.nasdaq.com/articles/stocks-rising-relative-price-strength-innoviva-2017-10-03", "https://www.nasdaq.com/articles/stocks-rising-relative-price-strength-innoviva-2017-10-06", "https://www.nasdaq.com/articles/stocks-watch-adamas-pharmaceuticals-sees-relative-strength-rating-jump-92-2017-10-06", "https://www.nasdaq.com/articles/stocks-rising-relative-strength-amgen-2017-10-05", "https://www.nasdaq.com/articles/stocks-flashing-renewed-technical-strength-acceleron-pharma-2017-09-29", "https://www.nasdaq.com/articles/flexion-therapeutics-sees-relative-strength-rating-improve-75-2017-09-29", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-hits-80-plus-relative-strength-rating-benchmark-2017-09-29", "https://www.nasdaq.com/articles/clovis-oncology-scores-relative-strength-rating-upgrade-2017-09-28", "https://www.nasdaq.com/articles/aerie-pharmaceuticals-sees-ibd-rs-rating-climb-73-2017-10-03", "https://www.nasdaq.com/articles/stocks-showing-market-leadership-sarepta-therapeutics-earns-91-rs-rating-2017-09-27", "https://www.nasdaq.com/articles/acceleron-pharma-reaches-80-plus-relative-strength-rating-benchmark-2017-09-27", "https://www.nasdaq.com/articles/stocks-flashing-renewed-technical-strength-innoviva-2017-09-27", "https://www.nasdaq.com/articles/3-bargain-biotech-stocks-you-can-buy-today-2017-09-26", "https://www.nasdaq.com/articles/global-blood-therapeutic-clears-technical-benchmark-hitting-80-plus-rs-rating-2017-09-26", "https://www.nasdaq.com/articles/acceleron-pharma-trying-close-key-technical-measure-2017-09-26", "https://www.nasdaq.com/articles/acorda-therapeutics-getting-closer-key-technical-measure-2017-09-26", "https://www.nasdaq.com/articles/stocks-watch-prothena-sees-relative-strength-rating-jump-81-2017-09-27", "https://www.nasdaq.com/articles/3-highest-growth-stocks-market-today-2017-09-25", "https://www.nasdaq.com/articles/interesting-cort-put-and-call-options-may-2018-2017-09-20", "https://www.nasdaq.com/articles/3-stocks-have-doubled-year-2017-09-14", "https://www.nasdaq.com/articles/pfizers-snda-for-bosulif-accepted-in-the-u.s.-and-europe-2017-08-30", "https://www.nasdaq.com/articles/7-buy-ranked-stocks-just-touched-new-all-time-highs-2017-08-30", "https://www.nasdaq.com/articles/top-ranked-momentum-stocks-to-buy-for-august-29th-2017-08-29", "https://www.nasdaq.com/articles/mylan-and-otsuka-ink-agreement-to-commercialize-deltyba-2017-08-25", "https://www.nasdaq.com/articles/cort-crosses-above-average-analyst-target-2017-09-25", "https://www.nasdaq.com/articles/3-highest-growth-stocks-market-today-2017-09-25", "https://www.nasdaq.com/articles/interesting-cort-put-and-call-options-may-2018-2017-09-20", "https://www.nasdaq.com/articles/3-stocks-have-doubled-year-2017-09-14", "https://www.nasdaq.com/articles/pfizers-snda-for-bosulif-accepted-in-the-u.s.-and-europe-2017-08-30", "https://www.nasdaq.com/articles/7-buy-ranked-stocks-just-touched-new-all-time-highs-2017-08-30", "https://www.nasdaq.com/articles/top-ranked-momentum-stocks-to-buy-for-august-29th-2017-08-29", "https://www.nasdaq.com/articles/mylan-and-otsuka-ink-agreement-to-commercialize-deltyba-2017-08-25", "https://www.nasdaq.com/articles/cort-crosses-above-average-analyst-target-2017-09-25", "https://www.nasdaq.com/articles/biodelivery-bdsi-ceo-mark-sirgo-to-retire-by-2017-end-2017-08-24", "https://www.nasdaq.com/articles/lannett-lci-q4-earnings-in-line-stock-up-on-solid-view-2017-08-24", "https://www.nasdaq.com/articles/three-stocks-breaking-out-2017-08-16", "https://www.nasdaq.com/articles/whats-retailer-do-2017-08-16", "https://www.nasdaq.com/articles/why-corcept-therapeutics-cort-could-be-positioned-for-a-surge-2017-08-14", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-corcept-therapeutics-cort-2017-08-09", "https://www.nasdaq.com/articles/top-ranked-momentum-stocks-to-buy-for-august-7th-2017-08-07", "https://www.nasdaq.com/articles/adamas-adms-dyskinesia-drug-gets-fda-approval-stock-soars-2017-08-25", "https://www.nasdaq.com/articles/corcept-cort-q2-earnings-beat-estimates-guidance-raised-2017-08-02", "https://www.nasdaq.com/articles/why-corcept-therapeutics-incorporated-stock-surged-higher-today-2017-08-02", "https://www.nasdaq.com/articles/health-care-sector-update-08022017-cortoncecotv-2017-08-02", "https://www.nasdaq.com/articles/cort-crosses-above-average-analyst-target-2017-08-01", "https://www.nasdaq.com/articles/ingalls-snyder-llc-buys-general-electric-co-delta-air-lines-inc-jpmorgan-chase-sells-2017", "https://www.nasdaq.com/articles/3-under-radar-stocks-healthcare-sector-2017-07-26", "https://www.nasdaq.com/articles/vertex-vrtx-triple-combination-cf-studies-data-positive-2017-07-19", "https://www.nasdaq.com/articles/corcept-cort-looks-good%3A-stock-moves-up-8.8-in-session-2017-08-03", "https://www.nasdaq.com/articles/corcept-therapeutics-focuses-on-korlyms-label-expansion-2017-07-13", "https://www.nasdaq.com/articles/why-is-corcepts-stock-up-more-than-60-so-far-this-year-2017-07-03", "https://www.nasdaq.com/articles/corcept-therapeutics-incorporated-3-charts-2017-06-26", "https://www.nasdaq.com/articles/corcept-cort-strives-to-commercialize-key-drug-korlym-2017-03-29", "https://www.nasdaq.com/articles/health-care-sector-update-03062017-corttgtxions-2017-03-06", "https://www.nasdaq.com/articles/health-care-sector-update-01312017-cortaezstenx-2017-01-31", "https://www.nasdaq.com/articles/3-stocks-expected-more-double-their-earnings-2017-2017-01-08", "https://www.nasdaq.com/articles/7-healthcare-stocks-with-a-rated-prospects-2017-04-21", "https://www.nasdaq.com/articles/nivalis-nvls-shares-down-after-merger-deal-with-alpine-2017-04-20", "https://www.nasdaq.com/articles/amag-files-for-fda-approval-of-subcutaneous-form-of-makena-2017-04-18", "https://www.nasdaq.com/articles/corcept-cort-up-18-since-earnings-report%3A-can-it-continue-2017-04-06", "https://www.nasdaq.com/articles/emergent-ebs-stock-up-on-multi-year-nuthrax-vaccine-deal-2016-10-03", "https://www.nasdaq.com/articles/top-3-growth-stocks-under-10-2016-09-29", "https://www.nasdaq.com/articles/ionis-biogen-complete-nusinersen-nda-submission-in-u.s.-2016-09-27", "https://www.nasdaq.com/articles/parexel-international-prxl-set-to-acquire-execupharm-2016-09-27", "https://www.nasdaq.com/articles/mid-day-market-update-conatus-jumps-following-announcement-licensing-deal-novartis-sucampo", "https://www.nasdaq.com/articles/novartis-ilaris-approved-for-extended-use-in-periodic-fever-2016-09-26", "https://www.nasdaq.com/articles/glaxo-jj-file-bla-for-rheumatoid-arthritis-drug-in-the-u.s.-2016-09-26", "https://www.nasdaq.com/articles/edwards-lifesciences-davita-healthcare-partners-corcept-therapeutics-and-cryolife", "https://www.nasdaq.com/articles/adamas-adms-parkinsons-disease-drug-positive-in-phase-iii-2016-09-21", "https://www.nasdaq.com/articles/aldeyra-therapeutics-aldx-worth-a-look%3A-stock-gains-7-2016-09-21", "https://www.nasdaq.com/articles/new-strong-buy-stocks-september-21st-2016-09-21", "https://www.nasdaq.com/articles/here-are-2-momentous-healthcare-stocks-buy-now-2016-09-21", "https://www.nasdaq.com/articles/array-arry-hits-52-week-high-on-positive-phase-iii-data-2016-09-27", "https://www.nasdaq.com/articles/novartis-nvs-presents-positive-data-on-cardiovascular-drug-2016-09-19", "https://www.nasdaq.com/articles/advanced-accelerator-aaap-worth-watching%3A-stock-jumps-6.2-2016-09-19", "https://www.nasdaq.com/articles/should-you-get-rid-of-forward-pharma-fwp-now-2016-09-14", "https://www.nasdaq.com/articles/nivalis-therapeutics-nvls-catches-eye%3A-stock-jumps-5.8-2016-09-14", "https://www.nasdaq.com/articles/glaxo-jj-file-for-rheumatoid-arthritis-drug-sirukumab-in-eu-2016-09-13", "https://www.nasdaq.com/articles/geron-gern-at-52-week-low-on-imetelstat-study-update-2016-09-13", "https://www.nasdaq.com/articles/auris-ears-advances-on-sudden-deafness-study-stock-up-2016-09-12", "https://www.nasdaq.com/articles/eli-lilly-lly-gets-favorable-chmp-opinion-for-olaratumab-2016-09-19", "https://www.nasdaq.com/articles/agios-agio-partner-celgene-to-file-for-enasidenib-stock-up-2016-09-08", "https://www.nasdaq.com/articles/gw-pharmaceuticals-gwph-stock-gains-on-buyout-rumors-2016-09-08", "https://www.nasdaq.com/articles/bristol-myers-orencia-gains-eu-approval-for-expanded-use-2016-09-07", "https://www.nasdaq.com/articles/biomarins-bmrn-brineura-review-period-extended-by-fda-2016-09-07", "https://www.nasdaq.com/articles/karyopharm-reports-positive-multiple-myeloma-study-data-2016-09-07", "https://www.nasdaq.com/articles/sage-therapeutics%3A-breakthrough-status-for-depression-drug-2016-09-07", "https://www.nasdaq.com/articles/novartis-nvs-reports-positive-data-on-ultibro-breezhaler-2016-09-06", "https://www.nasdaq.com/articles/4-growth-stocks-at-low-prices-to-counter-the-market-slump-2016-09-12", "https://www.nasdaq.com/articles/catalyst-firdapse-gets-orphan-status-for-myasthenia-gravis-2016-09-06", "https://www.nasdaq.com/articles/array-arry-oncology-drug-accepted-for-review-in-the-u.s.-2016-09-02", "https://www.nasdaq.com/articles/bet-on-these-5-profitable-stocks-for-big-returns-2016-09-02", "https://www.nasdaq.com/articles/roche-immuno-oncology-drug-tecentriq-positive-in-phase-iii-2016-09-01", "https://www.nasdaq.com/articles/roche-gets-fda-nod-for-emergency-use-of-zika-virus-test-2016-08-29", "https://www.nasdaq.com/articles/novartis-nvs-reports-positive-phase-iii-results-on-ms-drug-2016-08-26", "https://www.nasdaq.com/articles/mallinckrodt-to-divest-nuclear-imaging-business-for-%24690m-2016-08-25", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-corcept-therapeutics-parsley-energy-tri-pointe-group", "https://www.nasdaq.com/articles/catalyst-firdapse-gets-orphan-status-for-myasthenia-gravis-2016-09-06", "https://www.nasdaq.com/articles/array-arry-oncology-drug-accepted-for-review-in-the-u.s.-2016-09-02", "https://www.nasdaq.com/articles/bet-on-these-5-profitable-stocks-for-big-returns-2016-09-02", "https://www.nasdaq.com/articles/roche-immuno-oncology-drug-tecentriq-positive-in-phase-iii-2016-09-01", "https://www.nasdaq.com/articles/roche-gets-fda-nod-for-emergency-use-of-zika-virus-test-2016-08-29", "https://www.nasdaq.com/articles/what-falling-estimates-price-mean-for-merus-labs-international-msli-2016-08-22", "https://www.nasdaq.com/articles/horizon-hznp-rayos-receives-uspto-notice-of-allowance-2016-08-19", "https://www.nasdaq.com/articles/jj-jnj-seeks-eu-approval-for-darzalexs-expanded-use-2016-08-24", "https://www.nasdaq.com/articles/novartis-licenses-anti-pcsk9-antibody-to-cyon-therapeutics-2016-08-24", "https://www.nasdaq.com/articles/cempras-application-for-pneumonia-drug-validated-in-eu-2016-08-24", "https://www.nasdaq.com/articles/gilead-gild-truvada-gets-eu-approval-for-label-expansion-2016-08-23", "https://www.nasdaq.com/articles/roche-launches-accu-chek-blood-glucose-monitoring-system-2016-08-23", "https://www.nasdaq.com/articles/supernus-trokendi-xr-gets-fda-nod-for-migraine-in-adults-2016-08-22", "https://www.nasdaq.com/articles/what-falling-estimates-price-mean-for-merus-labs-international-msli-2016-08-22", "https://www.nasdaq.com/articles/horizon-hznp-rayos-receives-uspto-notice-of-allowance-2016-08-19", "https://www.nasdaq.com/articles/jj-jnj-seeks-eu-approval-for-darzalexs-expanded-use-2016-08-24", "https://www.nasdaq.com/articles/novartis-licenses-anti-pcsk9-antibody-to-cyon-therapeutics-2016-08-24", "https://www.nasdaq.com/articles/cempras-application-for-pneumonia-drug-validated-in-eu-2016-08-24", "https://www.nasdaq.com/articles/gilead-gild-truvada-gets-eu-approval-for-label-expansion-2016-08-23", "https://www.nasdaq.com/articles/roche-launches-accu-chek-blood-glucose-monitoring-system-2016-08-23", "https://www.nasdaq.com/articles/supernus-trokendi-xr-gets-fda-nod-for-migraine-in-adults-2016-08-22", "https://www.nasdaq.com/articles/what-falling-estimates-price-mean-for-merus-labs-international-msli-2016-08-22", "https://www.nasdaq.com/articles/horizon-hznp-rayos-receives-uspto-notice-of-allowance-2016-08-19", "https://www.nasdaq.com/articles/jj-jnj-seeks-eu-approval-for-darzalexs-expanded-use-2016-08-24", "https://www.nasdaq.com/articles/insys-therapeutics-starts-enrollment-in-cannabidiol-trial-2016-08-19", "https://www.nasdaq.com/articles/glaxo-pfizer-viiv-healthcare-starts-hiv-drug-combo-study-2016-08-17", "https://www.nasdaq.com/articles/oncogenex-down-on-poor-phase-iii-data-on-lead-cancer-drug-2016-08-17", "https://www.nasdaq.com/articles/aurinia-auph-stock-falls-on-poor-phase-ii-lupus-study-data-2016-08-16", "https://www.nasdaq.com/articles/jazz-jazz-q2-earnings-yy-lowers-earnings-outlook-2016-08-10", "https://www.nasdaq.com/articles/gw-pharma-gwph-incurs-narrower-than-expected-q3-loss-2016-08-10", "https://www.nasdaq.com/articles/inovio-ino-q2-loss-in-line-with-estimates-revenues-top-2016-08-09", "https://www.nasdaq.com/articles/adverum-advm-reports-narrower-than-expected-q2-loss-2016-08-11", "https://www.nasdaq.com/articles/why-corcept-therapeutics-cort-could-be-a-potential-winner-2016-08-09", "https://www.nasdaq.com/articles/endocyte-ecyt-q2-loss-wider-than-expected-revised-2016-08-09", "https://www.nasdaq.com/articles/horizon-hznp-earnings-up-y-y-keeps-16-view-stock-up-2016-08-09", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-logitech-international-sa-a10-networks-trinet-group-corcept", "https://www.nasdaq.com/articles/corcept-cort-reports-early-breast-cancer-data-on-korlym-2016-06-03", "https://www.nasdaq.com/articles/wednesday-511-insider-buying-report-cort-newm-2016-05-11", "https://www.nasdaq.com/articles/5-liquid-stocks-for-a-steady-flow-of-high-returns-2016-08-05", "https://www.nasdaq.com/articles/corcept-therapeutics-rose-18-march-heres-why-2016-04-06", "https://www.nasdaq.com/articles/corcept-therapeutics-cort-jumps%3A-stock-moves-up-9.6-2016-04-01", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-corcept-therapeutics-epizyme-geron-and-synthetic", "https://www.nasdaq.com/articles/galmed-pharmaceuticals-glmd-jumps%3A-stock-rises-7.9-2016-03-29", "https://www.nasdaq.com/articles/valeant-ceo-gets-subpoena-from-senate-aging-committee-2016-03-29", "https://www.nasdaq.com/articles/aerie-starts-dosing-in-registration-trial-mercury-2-on-roclatan-2016-03-29", "https://www.nasdaq.com/articles/4-surging-stocks-brokers-love-healthcare-sector-2016-03-28", "https://www.nasdaq.com/articles/corcept-cort-posts-in-line-q1-earnings-korlym-in-focus-2016-05-04", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-corcept-therapeutics-cort-2016-03-23", "https://www.nasdaq.com/articles/valeant-to-get-a-new-ceo-amid-turmoil-ackman-on-board-2016-03-22", "https://www.nasdaq.com/articles/valeant-pharmaceuticals-vrx-jumps%3A-stock-adds-7.4-2016-03-22", "https://www.nasdaq.com/articles/mckesson-mck-to-restructure-operations-lower-headcount-2016-03-21", "https://www.nasdaq.com/articles/walgreens-buys-amerisourcebergen-shares-per-warrants-2016-03-21", "https://www.nasdaq.com/articles/ucb-and-amgen-report-positive-data-on-osteoporosis-drug-2016-03-21", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-valeant-pharmaceuticals-international-corcept", "https://www.nasdaq.com/articles/roche-files-for-fda-approval-of-elecsys-brahms-assay-2016-03-24", "https://www.nasdaq.com/articles/bio-blast-pharma-orpn-in-focus%3A-stock-moves-up-54.5-2016-03-17", "https://www.nasdaq.com/articles/valeant-pharmaceuticals-vrx-in-focus-after-epic-decline-2016-03-17", "https://www.nasdaq.com/articles/3-hedge-funds-that-lost-hundreds-of-millions-on-valeant-stock-2016-03-17", "https://www.nasdaq.com/articles/valeant-trims-view-likely-to-face-credit-default-shares-fall-2016-03-16", "https://www.nasdaq.com/articles/catalyst-cprx-posts-in-line-q4-loss-fda-meeting-in-focus-2016-03-16", "https://www.nasdaq.com/articles/forward-pharma-fwp-jumps%3A-stock-adds-23.1-in-session-2016-03-15", "https://www.nasdaq.com/articles/immune-design-loss-wider-than-expected-pipeline-in-focus-2016-03-11", "https://www.nasdaq.com/articles/forget-valeant-buy-these-5-drug-stocks-instead-2016-03-17", "https://www.nasdaq.com/articles/radius-health-rdus-jumps%3A-stock-adds-15.5-in-session-2016-03-10", "https://www.nasdaq.com/articles/valeant-terminates-litigation-with-ro-pharmacy-2016-03-10", "https://www.nasdaq.com/articles/endocyte-ecyt-reports-narrower-than-expected-loss-in-q4-2016-03-03", "https://www.nasdaq.com/articles/mckesson-to-buy-canadian-pharmacy-chain-rexall-health-2016-03-03", "https://www.nasdaq.com/articles/corcepts-cort-q4-earnings-impress-pipeline-in-focus-2016-03-02", "https://www.nasdaq.com/articles/aerie-aeri-q4-loss-wider-than-expected-pipeline-in-focus-2016-03-02", "https://www.nasdaq.com/articles/concerts-early-stage-cystic-fibrosis-drug-shows-promise-2016-03-01", "https://www.nasdaq.com/articles/allergans-prior-approval-supplement-for-restasis-gets-crl-2016-03-11", "https://www.nasdaq.com/articles/novo-nordisk-presents-data-on-tresiba-and-semaglutide-2016-02-24", "https://www.nasdaq.com/articles/aerie-aeri-reports-positive-interim-results-on-rhopressa-2016-02-18", "https://www.nasdaq.com/articles/catalyst-cprx-down-on-fdas-refusal-to-file-firdapse-nda-2016-02-18", "https://www.nasdaq.com/articles/intercept-pharmaceuticals-icpt-soars-on-buyout-rumors-2016-02-16", "https://www.nasdaq.com/articles/catalyst-cprx-initiates-study-on-firdapse-for-musk-mg-2016-02-09", "https://www.nasdaq.com/articles/shires-nda-resubmission-for-lifitegrast-accepted-by-fda-2016-02-05", "https://www.nasdaq.com/articles/amerisourcebergen-beats-on-q1-earnings-narrows-outlook-2016-02-04", "https://www.nasdaq.com/articles/pacira-slips-to-q4-loss-misses-estimates-exparel-in-focus-2016-02-29", "https://www.nasdaq.com/articles/genocea-doses-patients-in-phase-iib-study-on-gen-003-2016-02-01", "https://www.nasdaq.com/articles/quality-systems-beats-q3-earnings-lags-revenue-estimates-2016-01-29", "https://www.nasdaq.com/articles/corcept-reports-preliminary-q4-earnings-revenues-line-2016-01-29", "https://www.nasdaq.com/articles/abbott-labs-abt-beats-on-q4-earnings-lags-on-revenues-2016-01-28", "https://www.nasdaq.com/articles/radius-rdus-collaborates-with-novartis-targeting-cancer-2016-01-28", "https://www.nasdaq.com/articles/oncogenex-cancer-drug-fails-to-show-pfs-in-phase-ii-trial-2016-01-21", "https://www.nasdaq.com/articles/roche-abbvies-leukemia-drug-gets-breakthrough-status-2016-01-21", "https://www.nasdaq.com/articles/conatus-up-on-fast-track-status-for-emricasan-in-the-u.s.-2016-02-04", "https://www.nasdaq.com/articles/intellipharmaceutics-up-on-positive-rexista-oxycodone-data-2016-01-15", "https://www.nasdaq.com/articles/gilead-seeks-approval-for-tenofovir-alafenamide-for-hbv-2016-01-13", "https://www.nasdaq.com/articles/immune-designs-immunotherapy-drugs-get-orphan-status-2016-01-11", "https://www.nasdaq.com/articles/cempra-slumps%3A-cemp-falls-10.5-in-session-2016-01-08", "https://www.nasdaq.com/articles/teva-teva-and-checkpoint-therapeutics-ink-oncology-deal-2016-01-08", "https://www.nasdaq.com/articles/conatus-cnat-reports-positive-phase-ii-data-on-emricasan-2016-01-07", "https://www.nasdaq.com/articles/auris-medical-ears-catches-eye%3A-stock-moves-up-16.9-2016-01-06", "https://www.nasdaq.com/articles/novartis-gets-fda-nod-for-label-expansion-of-cosentyx-2016-01-18", "https://www.nasdaq.com/articles/baxalta-bxlt-inks-immuno-oncology-deal-with-symphogen-2016-01-05", "https://www.nasdaq.com/articles/kempharm-expands-pipeline-to-include-pain-candidate-kp746-2016-01-04", "https://www.nasdaq.com/articles/minerva-nerv-looks-good%3A-stock-moves-6.8-higher-2016-01-04", "https://www.nasdaq.com/articles/vivus-to-regain-u.s.-and-canada-stendra-rights-from-endo-2016-01-04", "https://www.nasdaq.com/articles/minervas-schizophrenia-drug-application-accepted-by-fda-2015-12-30", "https://www.nasdaq.com/articles/chimerix-cmrx-tanks-on-disappointing-brincidofovir-data-2015-12-29", "https://www.nasdaq.com/articles/kamada-kmda-reports-encouraging-data-on-rabies-drug-2015-12-29", "https://www.nasdaq.com/articles/gilead-up-on-encouraging-data-on-tenofovir-alafenamide-2016-01-06", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-edge-lower-cal-maine-misses-q2-expectations-2015-12-24", "https://www.nasdaq.com/articles/adamas-adms-surges-on-positive-data-on-lead-candidate-2015-12-24", "https://www.nasdaq.com/articles/celyads-c-cure-ind-authorized-in-u.s.-for-phase-iii-study-2015-12-23", "https://www.nasdaq.com/articles/celgene-celg-settles-revlimid-patent-litigation-with-natco-2015-12-23", "https://www.nasdaq.com/articles/achaogen-akao-catches-eye%3A-stock-adds-6.4-in-session-2015-12-22", "https://www.nasdaq.com/articles/ohr-pharmaceutical-ohrp-worth-watching%3A-stock-up-10.5-2015-12-22", "https://www.nasdaq.com/articles/aveo-licenses-tivozanib-european-rights-to-eusa-pharma-2015-12-22", "https://www.nasdaq.com/articles/gw-pharmaceuticals-publishes-encouraging-epidiolex-data-2015-12-28", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-edge-lower-cal-maine-misses-q2-expectations-2015-12-24", "https://www.nasdaq.com/articles/catalyst-pharmaceuticals-reveals-data-on-neurological-drug-2015-12-17", "https://www.nasdaq.com/articles/valeant-slashes-view-for-q4-and-2015-issues-2016-outlook-2015-12-17", "https://www.nasdaq.com/articles/zoetis-zts-declares-14.5-hike-in-quarterly-dividend-2015-12-17", "https://www.nasdaq.com/articles/clovis-clvs-rociletinibs-review-period-extended-by-fda-2015-12-16", "https://www.nasdaq.com/articles/bristol-myers-neon-therapeutics-ink-immuno-oncology-deal-2015-12-16", "https://www.nasdaq.com/articles/valeant-in-price-cut-deal-with-walgreens%3A-will-investors-gain-2015-12-16", "https://www.nasdaq.com/articles/biomarins-bmrn-kyndrisa-review-period-extended-by-fda-2015-12-21", "https://www.nasdaq.com/articles/akebia-up-on-mitsubishi-tanabe-pharma-deal-for-vadadustat-2015-12-15", "https://www.nasdaq.com/articles/aduros-crs-207-gvax-pancreas-gets-orphan-status-in-eu-2015-12-15", "https://www.nasdaq.com/articles/atara-plunges-on-poor-results-from-phase-ii-pinta-745-study-2015-12-15", "https://www.nasdaq.com/articles/pacira-resolves-litigation-related-to-exparel-with-the-fda-2015-12-15", "https://www.nasdaq.com/articles/corcept-releases-initial-data-on-korlym-halaven-combination-2015-12-15", "https://www.nasdaq.com/articles/roches-alecensa-approved-in-the-u.s.-for-lung-cancer-2015-12-14", "https://www.nasdaq.com/articles/otonomys-ear-infection-drug-otiprio-approved-in-the-u.s.-2015-12-14", "https://www.nasdaq.com/articles/evotec-spero-deal-extended-for-gram-negative-bacteria-2015-12-16", "https://www.nasdaq.com/articles/auris-medical-ears-shows-strength%3A-stock-rises-22.4-2015-12-10", "https://www.nasdaq.com/articles/sanofis-dengue-vaccine-dengvaxia-gets-mexican-approval-2015-12-10", "https://www.nasdaq.com/articles/oncogenex-to-continue-with-borealis-2-study-on-apatorsen-2015-12-10", "https://www.nasdaq.com/articles/mei-pharma-meip-worth-watching%3A-stock-gains-5.4-2015-12-09", "https://www.nasdaq.com/articles/how-corcept-therapeutics-cort-stock-stands-out-in-a-strong-industry-2015-12-07", "https://www.nasdaq.com/articles/progenics-pgnx-reaches-target-enrolment-in-azedra-study-2015-12-04", "https://www.nasdaq.com/articles/cytori-reports-positive-top-line-data-on-eccs-50-yet-again-2015-12-03", "https://www.nasdaq.com/articles/raptor-reports-efficacy-data-from-cyst-hd-study-on-rp103-2015-12-11", "https://www.nasdaq.com/articles/biolinerx-blrx-worth-watching%3A-stock-rises-11.3-2015-12-02", "https://www.nasdaq.com/articles/celyad-starts-2nd-cohort-of-phase-i-on-nkg2d-car-t-cell-2015-12-02", "https://www.nasdaq.com/articles/affimed-afmd-shows-strength%3A-stock-moves-6.7-higher-2015-12-01", "https://www.nasdaq.com/articles/mallinckrodt-mnk-sells-contrast-media-delivery-systems-2015-11-30", "https://www.nasdaq.com/articles/merck-kgaa-pfizers-avelumab-may-get-orphan-status-in-eu-2015-11-27", "https://www.nasdaq.com/articles/ocular-begins-second-phase-iii-allergic-conjunctivitis-study-2015-11-26", "https://www.nasdaq.com/articles/biomarins-vimizim-gets-nice-recommendation-in-england-2015-11-24", "https://www.nasdaq.com/articles/zafgen-sinks-2nd-death-obesity-study-full-clinical-hold-2015-12-03", "https://www.nasdaq.com/articles/surmodics-buys-balloon-catheter-maker-creagh-medical-2015-11-23", "https://www.nasdaq.com/articles/merus-labs-international-msli-jumps%3A-stock-rises-6.4-2015-11-20", "https://www.nasdaq.com/articles/ohr-pharmaceutical-ohrp-jumps%3A-stock-moves-8.1-higher-2015-11-20", "https://www.nasdaq.com/articles/aduro-adro-creates-subsidiary-aduro-biotech-europe-2015-11-20", "https://www.nasdaq.com/articles/david-swensens-transactions-show-diversity-portfolio-2015-11-19", "https://www.nasdaq.com/articles/earnings-estimates-moving-higher-for-corcept-therapeutics-cort%3A-time-to-buy-2015-11-19", "https://www.nasdaq.com/articles/amag-receives-another-crl-for-single-dose-vial-of-makena-2015-11-19", "https://www.nasdaq.com/articles/amag-responds-to-fdas-crl-for-single-dose-vial-of-makena-2015-11-24", "https://www.nasdaq.com/articles/strength-seen-in-fibrogen-fgen%3A-stock-rises-6.3-2015-11-18", "https://www.nasdaq.com/articles/arqules-drug-gets-orphan-drug-status-for-proteus-syndrome-2015-11-18", "https://www.nasdaq.com/articles/radius-health-seeks-approval-for-abaloparatide-sc-in-eu-2015-11-18", "https://www.nasdaq.com/articles/is-corcept-therapeutics-an-incredible-momentum-stock-3-reasons-why-cort-will-be-tough-to", "https://www.nasdaq.com/articles/immune-design-posts-narrower-than-expected-loss-for-q3-2015-11-13", "https://www.nasdaq.com/articles/surmodics-srdx-q4-earnings-revenues-beat-estimates-2015-11-12", "https://www.nasdaq.com/articles/otonomy-otic-shows-strength%3A-stock-moves-up-13.7-2015-11-12", "https://www.nasdaq.com/articles/spectrum-sppi-up-on-selling-zevalin-rights-to-mundipharma-2015-11-19", "https://www.nasdaq.com/articles/immune-design-starts-mid-stage-soft-tissue-sarcoma-trial-2015-11-12", "https://www.nasdaq.com/articles/can-the-rally-in-corcept-therapeutics-cort-shares-continue-2015-11-11", "https://www.nasdaq.com/articles/catalyst-pharmaceuticals-q3-loss-narrower-than-expected-2015-11-10", "https://www.nasdaq.com/articles/inovios-ino-q3-earnings-impress-revenues-up-y-y-2015-11-10", "https://www.nasdaq.com/articles/avalanche-aavl-reports-wider-than-expected-loss-in-q3-2015-11-10", "https://www.nasdaq.com/articles/seattle-genetics-sgen-loss-widens-y-y-outlook-upped-2015-10-30", "https://www.nasdaq.com/articles/novo-nordisk-nvo-beats-on-q3-earnings-maintains-view-2015-10-30", "https://www.nasdaq.com/articles/alnylam-alny-reports-positive-interim-data-on-aln-pcssc-2015-11-12", "https://www.nasdaq.com/articles/immune-design-starts-mid-stage-soft-tissue-sarcoma-trial-2015-11-12", "https://www.nasdaq.com/articles/merck-kgaa-pfizers-avelumab-gets-fast-track-status-2015-10-08", "https://www.nasdaq.com/articles/merck-kgaas-pipeline-on-track-updates-key-rd-projects-2015-10-02", "https://www.nasdaq.com/articles/novavaxs-respiratory-vaccine-study-data-fail-to-impress-2015-09-30", "https://www.nasdaq.com/articles/why-valeants-vrx-shares-plummeted-in-monday-trading-2015-09-29", "https://www.nasdaq.com/articles/shires-shpg-vyvanse-u.s.-patent-validated-expiry-in-2023-2015-09-25", "https://www.nasdaq.com/articles/oncogenex-down-on-failure-of-pancreatic-cancer-study-2015-09-24", "https://www.nasdaq.com/articles/dr.-reddys-rdy-q2-earnings-rise-y-y-biosimilars-in-focus-2015-10-30", "https://www.nasdaq.com/articles/valeants-glaucoma-drug-accepted-for-review-by-the-fda-2015-09-23", "https://www.nasdaq.com/articles/amerisourcebergen-launches-%242.4b-share-buyback-program-2015-09-22", "https://www.nasdaq.com/articles/shires-non-stimulant-intuniv-approved-in-europe-for-adhd-2015-09-22", "https://www.nasdaq.com/articles/mediwound-mdwd-looks-good%3A-stock-jumps-6-2015-09-17", "https://www.nasdaq.com/articles/merck-kgaa-continues-restructuring-efforts-growth-in-focus-2015-09-16", "https://www.nasdaq.com/articles/new-strong-buy-stocks-for-september-16th-2015-09-16", "https://www.nasdaq.com/articles/new-strong-buy-stocks-for-september-11th-2015-09-11", "https://www.nasdaq.com/articles/ampio-ampe-starts-final-phase-iii-study-on-knee-pain-drug-2015-09-23", "https://www.nasdaq.com/articles/pacira-files-lawsuit-vs.-fda-over-exparel-marketing-2015-09-09", "https://www.nasdaq.com/articles/endocyte-reveals-overall-survival-data-from-target-study-2015-09-08", "https://www.nasdaq.com/articles/new-strong-buy-stocks-for-september-8th-2015-09-08", "https://www.nasdaq.com/articles/others-overlooked-corcept-therapeutics-cort-should-you-buy-it-now-2015-09-08", "https://www.nasdaq.com/articles/juniper-pharmaceuticals-jnp-rises%3A-stock-jumps-5.6-2015-09-03", "https://www.nasdaq.com/articles/novartis-nvs-launches-zarxio%3A-first-biosimilar-in-the-u.s.-2015-09-03", "https://www.nasdaq.com/articles/collegium-pharmaceutical-coll-in-focus%3A-stock-tumbles-14-2015-09-02", "https://www.nasdaq.com/articles/tetraphases-ttph-antibiotic-fails-in-phase-iii-study-2015-09-09", "https://www.nasdaq.com/articles/bristol-myers-to-pay-up-to-%241.25b-for-right-to-buy-promedior-2015-09-01", "https://www.nasdaq.com/articles/corcept-therapeutics-cort-jumps%3A-stock-moves-up-10.9-2015-08-27", "https://www.nasdaq.com/articles/lannett-company-lci-in-focus%3A-stock-moves-7.4-higher-2015-08-27", "https://www.nasdaq.com/articles/sucampo-to-acquire-r-tech-ueno-for-about-%24278-million-2015-08-27", "https://www.nasdaq.com/articles/why-bellicum-pharmaceuticals-blcm-could-be-positioned-for-a-slump-2015-08-26", "https://www.nasdaq.com/articles/shire-inks-deal-with-sanquin-to-expand-cinryze-production-2015-08-26", "https://www.nasdaq.com/articles/bear-day-jazz-pharma-jazz-2015-08-25", "https://www.nasdaq.com/articles/new-strong-buy-stocks-for-september-1st-2015-09-01", "https://www.nasdaq.com/articles/roche-to-buy-kapa-biosystems-boost-diagnostics-business-2015-08-20", "https://www.nasdaq.com/articles/new-strong-buy-stocks-for-august-20th-2015-08-20", "https://www.nasdaq.com/articles/corcept-therapeutics-cort%3A-an-off-the-radar-potential-winner-2015-08-14", "https://www.nasdaq.com/articles/immune-designs-q2-loss-narrows-y-y-focus-on-pipeline-2015-08-13", "https://www.nasdaq.com/articles/bristol-myers-cancer-drug-opdivo-fda-action-date-delayed-2015-08-13", "https://www.nasdaq.com/articles/catalyst-pharmaceuticals-loss-wider-y-y-firdapse-in-focus-analyst-blog-2015-08-11", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-q2-loss-wider-revenues-up-analyst-blog-2015-08-11", "https://www.nasdaq.com/articles/is-valeants-vrx-%241b-buy-of-addyi-maker-a-prudent-move-2015-08-21", "https://www.nasdaq.com/articles/roche-to-buy-kapa-biosystems-boost-diagnostics-business-2015-08-20", "https://www.nasdaq.com/articles/radius-health-q2-loss-wider-than-expected-narrower-y-y-analyst-blog-2015-08-07", "https://www.nasdaq.com/articles/orexigen-2q-loss-wider-expected-settles-takeda-analyst-blog-2015-08-07", "https://www.nasdaq.com/articles/merck-kgaas-net-income-up-y-y-2015-view-retained-analyst-blog-2015-08-07", "https://www.nasdaq.com/articles/medivation-tops-q2-earnings-ups-view-xtandi-impresses-analyst-blog-2015-08-07", "https://www.nasdaq.com/articles/corcepts-q2-loss-narrower-than-expected-view-narrowed-analyst-blog-2015-08-06", "https://www.nasdaq.com/articles/roche-earnings-down-y-y-oncology-immunology-drive-sales-analyst-blog-2015-07-24", "https://www.nasdaq.com/articles/mallinckrodt-to-acquire-therakos-boost-hospital-business-2015-08-11", "https://www.nasdaq.com/articles/valeant-vrx-beats-on-q2-earnings-revenues-ups-view-analyst-blog-2015-07-24", "https://www.nasdaq.com/articles/mid-day-market-update-dow-dips-over-1-harley-davidson-shares-rise-earnings-beat-2015-07-21", "https://www.nasdaq.com/articles/corcept-therapeutics-korlym-positive-in-breast-cancer-study-analyst-blog-2015-05-15", "https://www.nasdaq.com/articles/corcept-therapeutics-reports-wider-q1-loss-revenue-miss-analyst-blog-2015-05-08", "https://www.nasdaq.com/articles/3-soaring-biotech-stocks-under-10-are-they-buys-2015-04-22", "https://www.nasdaq.com/articles/health-care-sector-update-04212015-snta-cort-gnca-2015-04-21", "https://www.nasdaq.com/articles/corcept-therapeutics-cort-looks-good%3A-stock-up-83.9-tale-of-the-tape-2015-04-09", "https://www.nasdaq.com/articles/shires-shpg-q2-earnings-lag-estimates-2015-view-raised-analyst-blog-2015-07-24", "https://www.nasdaq.com/articles/valeant-vrx-beats-on-q2-earnings-revenues-ups-view-analyst-blog-2015-07-24", "https://www.nasdaq.com/articles/will-corcept-cort-continue-to-surge-higher-tale-of-the-tape-2014-12-15", "https://www.nasdaq.com/articles/moving-average-crossover-alert%3A-corcept-therapeutics-cort-tale-of-the-tape-2014-12-11", "https://www.nasdaq.com/articles/esperion-therapeutics-slumps%3A-espr-falls-6.3-in-session-tale-of-the-tape-2014-10-13", "https://www.nasdaq.com/articles/ptc-therapeutics-ptct-crumbles%3A-stock-falls-by-5.5-tale-of-the-tape-2014-10-13", "https://www.nasdaq.com/articles/sector-update-health-care-stocks-see-modest-declines-2014-08-06", "https://www.nasdaq.com/articles/corcepts-warrants-exercised-invest-in-korlym-pipeline-analyst-blog-2015-04-02", "https://www.nasdaq.com/articles/corcept-therapeutics-cort-jumps%3A-stock-rises-14.5-tale-of-the-tape-2015-03-12", "https://www.nasdaq.com/articles/corcept-therapeutics-inc-cort-new-analyst-report-zacks-equity-research-zacks-equity", "https://www.nasdaq.com/articles/will-corcept-cort-continue-to-surge-higher-tale-of-the-tape-2014-12-15", "https://www.nasdaq.com/articles/moving-average-crossover-alert%3A-corcept-therapeutics-cort-tale-of-the-tape-2014-12-11", "https://www.nasdaq.com/articles/esperion-therapeutics-slumps%3A-espr-falls-6.3-in-session-tale-of-the-tape-2014-10-13", "https://www.nasdaq.com/articles/pipeline-progress-at-corcept-analyst-blog-2013-12-16", "https://www.nasdaq.com/articles/sector-update-health-care-2014-08-06", "https://www.nasdaq.com/articles/corcept-therapeutics-cort-in-focus%3A-stock-rises-5.8-tale-of-the-tape-2014-05-12", "https://www.nasdaq.com/articles/corcept-plunges-on-study-results-analyst-blog-2014-05-08", "https://www.nasdaq.com/articles/corcept-therapeutics-cort%3A-strong-industry-solid-earnings-estimate-revisions-tale-of-the", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-corcept-analyst-blog-2013-05-07", "https://www.nasdaq.com/articles/corcepts-loss-narrows-in-4q-analyst-blog-2013-03-14", "https://www.nasdaq.com/articles/corcept-provides-4q-2012-outlook-analyst-blog-2013-02-15", "https://www.nasdaq.com/articles/company-news-for-february-22-2012-corporate-summary-2012-02-22", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-corcept-analyst-blog-2013-11-08", "https://www.nasdaq.com/articles/top-20-most-undervalued-healthcare-stocks-target-price-2011-01-14", "https://www.nasdaq.com/articles/regeneron-wins-fda-approval-eye-drug-3-companies-approval-2011-12-03"], "Content": []}